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Behorende bij het proefschrift 
, .... i.> Ora antidiabetic drugs and cardiac remodeling 
Meimei Yin 
I. In addition to hypertrophy, fibrosis, and apoptosis, myocardial metabolism also plays a 
pivotal role in cardiac remodeling. (This thesis) 
2. Comparable to the renin-angiotensin system, the incretin system is not only working 
systemically but also exerts specific local tissue dependent effects. (This thesis) 
3. Diabetes and heart failure are strongly interrelated; they can aggravate and provoke each 
other. This should be a strong focus for designing relevant new therapeutic strategies. (This 
thesis) 
4. Observational data suggest that metformin and GLP-1 may be beneficial in diabetic patients 
with cardiovascular disease independent of their effect on glucose metabolism. (This thesis). 
5. AMPK acts as a metabolic master switch regulating several intracellular systems including 
the cellular uptake of glucose, fatty acids oxidation and the biogenesis of glucose transporter 
4 (GLUT4), protein synthesis and mitochondria. (This thesis) 
6. If you think research is expensive, then try disease. Mary Lasker ( 1900-1994) 
7. Success is going from failure to failure without losing enthusiasm. 
-Winston Churchill 
s. ..t�:§'7](, 7JcflWJJJ!ltililii�� 
The best (man] is like water. 
Water is good; it benefits all things and does not compete with them. 
It dwells in [lowly] places that all disdain. 
This is why it is so near to Tao 
Lao-tzu (Chinese philosopher, 604 -531 BC). 
9. The most important part to get a PhD degree is not to get the title of Doctor, but to develop 
the skills to be a philosopher. 
10. For Dutch people, there is a clear line between work and holiday; but Chinese people are 
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Heart failure is the common end-stage phase of most cardiac diseases and a leading 
cause of death in the developed countries. The most common definition of heart failure 
is "A pathophysiological state in which an abnormality of cardiac function is 
responsible for the failure of the heart to pump blood at a rate commensurate with the 
requirement of the metabolizing tissues" 1• Five-year survival rate of patients is around 
50% after a diagnosis of heart failure 2• There is a dramatic increase in the number of 
persons who will develop heart failure and heart failure-related diagnosis, which has 
resulted in a heavy burden to the health care expenditure in past decades '· 3. 
As said, the etiology of heart failure is diverse, as many cardiac and also non­
cardiac diseases may ultimately manifest as heart failure. Most common causes for 
heart failure are coronary artery disease, hypertension, valvular disease, congenital 
heart disease, diabetes, and arrhythmias, amongst others 4• The initial injury is followed 
by a maladaptive compensatory response, referred to as cardiac remodeling 5• Different 
causes of heart failure develop differently, with distinct patterns and time course, as 
shown in figure I. An important distinction is heart failure with reduced ejection 
fraction (HFREF) vs. heart failure with preserved ejection fraction (HFPEF). Chief 
cause for HFREF is myocardial infarction, followed by pronounced remodeling and 
changing shape of the left ventricle, leading to systolic heart failure. Chief cause for 
HFPEF is hypertension, with or without diabetes mcllitus. However, it is important to 
realize that both patients with a myocardial infarction and patients with hypertension 
with or without diabetes may pass through an HFPEF period into HFREF 6• 
The early typical clinical symptoms of heart failure include fatigue and 
shortness of breath which exacerbates on exertion 1• However, on longer term, 
pathophysiology and clinical manifestations of heart failure arc typical for a multi­
system disease, since not only the heart is affected, but other organs, including kidneys, 
lungs, muscle, liver, bone marrow and other organs arc also affected and show 
pathophysiological changes and damage. The last decades, many new insights into the 
pathophysiology of heart failure have been made. These possible molecular 
mechanisms of heart failure involve cardiomyocyte apoptosis, myocardial fibrosis, and 
dysfunction of myocyte metabolism 5• 7• 8. However, the precise pathophysiological 
mechanisms of heart failure are still incompletely understood. 
Although pharmacological interventions attenuate the progression of the disease, 
mortality still remains high and patients still suffer a poor outcome 9• 10• Therefore, new 
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Figure 1 Time course and pattern of development of heart failure primarily caused by 
myocardial infarction (MI), and of heart failure primarily caused by hypertension (Hl), with 
or without mellitus (DM)Both patients with an MI and patients with HT may pass through an 
SHF period. Sanderson J E. Heart, 2007.Reprinted with permission from the Publisher. 
Type 2 diabetes mellitus 
Type 2 diabetes mellitus is by far the most common type of diabetes (type 1 diabetes 
mellitus being the other main type). In this thesis, diabetes simply refers to type 2 
diabetes mellitus. The prevalence of diabetes is growing rapidly and it is associated 
with both lifestyle and genetic factors, such as obesity, sedentary lifestyle, older age, 
family history of diabetes 11, especially in western societies, but also in developing 
countries 12• The epidemic of diabetes is predicted to be one of the major challenges of 
health care in the 21st century. 
Diabetes is a metabolic disorder characterized by insulin resistance or defective 
insulin secretion. Insulin is synthesized and secreted by the p cells in the islets of 
Langerhans, which are the regions of the pancreas that contain its endocrine (i.e., 
hormone-producing) cells. Insulin plays an important role in the regulation of glucose 
metabolism. Reduced insulin sensitivity or deficient insulin levels result in a high body 
glucose level, which is called hyperglycemia, and on the long term, after a subclinical 
phase before the clinical presentation shows, this may turn into diabetes. 
The classic symptoms of diabetes are polyuria (frequent urination), polydipsia 
(increased thirst), polyphagia (increased hunger), fatigue and weight loss. Diabetes is 
often diagnosed as hyperglycemia, and long-term high glucose levels result in chronic 
diabetic complications which affect many organs, such as heart, kidney, eyes and 




down the development and progression of the clinical complications and improve 
outcome. Current therapies include lifestyle intervention through diet changes and 
exercise 11• When lifestyle intervention is not sufficient, oral antidiabetic drugs are 
recommended. Eventually, insulin treatment is needed. 
Diabetes is associated with hyperglycemia, hyperinsulinemia, dyslipidemia, and 
an inflammatory state. All of these features affect the organs, and diabetes-associated 
end organ damage is the main reason for diabetes-related morbidity and mortality. 
Cardiovascular disease, such as hypertension, myocardial infarction or heart failure, is 
the most common complication of diabetes, which in fact accounts for 80% of the 
mortality in the diabetic population. The Framingham study showed that a high 
incidence of congestive heart failure exist in diabetic subjects: a 2.4-fold increase in 
diabetic men and a 5-fold increase in diabetic women independent of age, hypertension 
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Figure 2 The proportion of patients with hospitalization for CHF ( chronic heart failure divided into 
classes of glycemia at baseline. IFG indicates impaired fasting glucose. Held C et al, Circulation, 
2007, reprinted with permission of the Publisher. 
Heart failure and diabetes 
Heart failure and diabetes seem to have a close relationship with each other, since 20-
30% of heart failure patients also have diabetes 14• Vice versa, patients with diabetes 
have a high likelihood of developing heart failure. As shown in figure 2, patients with 
hyperglycemia, insulin resistance and diabetes have much higher incidence to develop 
12 
General introduction 
incident heart failure 15• So, diabetes mellitus is considered as a well-recognized risk 
factor for heart failure. 
As discussed, the most common connection between diabetes and heart failure is 
II atherosclerosis and coronary artery disease 8, which may cause myocardial infarction, 
and cause heart failure 16• Diabetes increases the risk for myocardial infarction, 
followed by a process of myocardial remodeling, in the end resulting in heart failure. 
Interestingly, part of the incident heart failure associated with diabetes is observed in 
the absence of cardiovascular disease, myocardial infarction, or other causes, but it 
seems that glycometabolic dysregulation per se may cause heart failure by itself. This 
entity is called "diabetic cardiomyopathy''. It manifests as cardiac dysfunction in 
diabetes patients, which is mainly characterized by myocardial hypertrophy and 
diastolic dysfunction (although cardiac dilatation and systolic dysfunction may also 
occur), independent of the coexistence of ischemic heart disease or hypertension 17• 
However, the link between diabetes and cardiovascular disease is only partially 
understood. Multiple mechanisms play a role: sustained hyperglycemia can result in 
overload of cellular Ca2+, activation of the renin-angiotensin system, increased 
oxidative stress, mitochondrial dysfunction and altered myocardial substrate 
metabolism, which is shown as increased lipolysis, impaired myocardial glucose 
uptake and utilization and increased fatty acid (FA) oxidation 12•18• As captured in 
figure 3, in addition to other causes like ischemic heart disease, hypertension, valvalur 
disease, endothelial dysfunction, such diabetes-specific factors may also contribute to 
increased L V diastolic stiffness, and result in diastolic dysfunction. 
In line with these mechanistic insights, several clinical post-hoc analyses from 
large scale trials showed that diabetes is a predictor of a worse prognosis and outcome 
of heart failure. The Studies of Left Ventricular Dysfunction (SOL VD) Prevention and 
Treatment trials showed that diabetes accelerated the progression of myocardial 
dysfunction 19• These findings were confirmed by Das et al. who showed that diabetic 
patients had an increased risk of progression to symptomatic heart failure, 
hospitalization and death for heart failure compared with patients with L V dysfunction 
due to ischemia without diabetes 20• An analysis of the CHARM (Candesartan in Heart 
failure: Assessment of Reduction in Mortality and morbidity) program demonstrated 
that diabetes was associated with a greater relative risk of cardiovascular death or heart 
failure hospitalization in patients with preserved ejection fraction (HFPEF) than in 
patients with reduced EF (HFREF) 21• Finally, also in elderly patients with heart failure 
(�70 years of age), in whom comorbidity including diabetes is very common; diabetes 
is associated with a worse prognosis 22• 
Clearly, we have convincing data showing that diabetes as co-morbidity for 
heart failure patients is associated with worse outcome. However, we have limited data 
13 
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as to what diabetes treatment is best for heart failure patients, and if antidiabetic drugs 
my improve heart failure outcome. 
Diastolic dysfunction and 
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Figure 3 Overview of interactions between the myocardial and vascular changes present in diabetic hearts 
and their contribution to diabetic cardiomyopathy and heart failure. Modified from Asghar O et al. Clinical 
Science (2009) 116, 741-760. Reprinted with permission. 
Oral antidiabetic drugs 
Today, a variety of treatments is available to clinicians to treat patients with type 2 
diabetes. In addition to dietary and physical activity interventions, pharmacological 
therapies are playing a central role 1 1• There are five classical types of anti-diabetic 
drugs: biguanides, sulfonylureas, meglitinides, thiazolidinediones, and a-glucosidase 
inhibitors. Novel compom1ds have recently been introduced: the incretin mimetic drugs 
(GLP-1 analogues), the dipeptidyl peptidase (DPP-4) inhibitors, the dual peroxisome 
proliferator-activated receptors (PPAR) agonists and the amylin mimetic drugs 23• 
There are no prospective trials evaluating if antidiabetic drugs affect heart 
failure outcome, however, there is data available to give us directions which drugs 
should be first choice. The UKPDS (United Kingdom Prospective Diabetes Study) 
demonstrated that long-term metformin treatment significantly reduced incidence of 
myocardial infarction and diabetes-related mortality in overweight and obese patients, 
and meta-analysis have shown that metformin improves clinical outcome and reduces 
all-cause mortality compared to other treatments in patients who had both heart failure 
and diabetes mellitus 24' 25• In experimental studies, metformin also showed beneficial 
14 
General introduction 
effects on cardiac function by the activation of AMPK. Also the relatively novel 
incretin hormones and DPP-4 inhibitors are reported to play a protective effect on the 
cardiovascular system. The actions of GLP-1 on cardiovascular system include I] 
improvement of endothelial function, cardiac function and myocardial glucose uptake 
26• From these data, the suggestion may arise that some oral anti-diabetic agents may 
exert cardioprotective effects. 
Aims of this thesis 
Aims of this thesis were: 1) In chapter 2, we reviewed the published data on oral 
antidiabetic drugs in experimental cardiac remodeling and HF; 2) In chapter 3, we 
evaluated the cardioprotective effects of metformin in post-MI heart failure; 3) In 
chapter 4, we evaluated the cardioprotective effects of the DPP-4 inhibitor vildagliptin, 
either as early or as late intervention in post-MI heart failure; 4) In chapter 5, we 
investigated the protective effects on DPP-4 inhibitor vildagliptin on the early stage of 
diabetic cardiomyopathy and explore the molecular mechanisms of diabetic 
cardiomyopathy; 5) In chapter 6, we evaluated the effects diabetes and in subjects at 
risk for developing heart failure, who underwent coronary artery bypass grafting ( data 
from the IMAGINE trial), and 6) In chapter 7, we summarized our findings and 
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Variable effects of anti-diabetic drugs in animal 
models of myocardial ischemia and remodeling: 
lessons for the cardiologist 
Meimei Yin, Maxi Meissner, Wiek H. van Gilst, Rudolf A. de Boer 
University Medical Center Groningen, University of Groningen, Department of 




Diabetes and heart failure are very prevalent and it has been demonstrated that 
they affect each other mutually. Novel therapies to reduce post-myocardial infarction 
(Ml) remodeling which subsequently leads to heart failure are urgently needed, 
especially in diabetic patients. Clinical studies have suggested that some agents, like 
mctformin, exert a cardiovascular protective role in heart failure patients with diabetes, 
whereas other oral antidiabetic against may be disadvantageous. Herc, we provide an 
overview of oral antidiabetic drugs on post-MI animal studies with respect to their 
cardiospecific effects. The aim of the current paper is to summarize the experimental 
data of the most commonly subscribed anti-diabetic agents (biguanidcs, sulfonylurcas, 
thiazolidincdioncs) on diabetes and heart failure and to compare these with the data 
available for the newer compounds (the incrctin mimetic drugs glucagon-like peptide 1 
(GLP-1) and the dipcptidyl peptidase (DPP-4) inhibitors. Metformin has proven effects 
in ameliorating cardiac remodeling in different models of heart failure. Sulfonylurea 
derivatives are controversial with respect to their direct effects on the cardiovascular 
system. G LP- 1 has a potential to play a beneficial effect on cardiovascular system. 
Thiazolidinediones are beneficial against myocardial ischemia-reperfusion injury but 
that their effects on post-MI remodeling are less clear, and clinical studies raised 
concerns with respect to their cardiovascular safety. Altogether, the available 
experimental evidence indicates that some anti diabetic agents should be preferred over 
others if cardioprotective effects arc warranted. These experimental clues should be 
confirmed in clinical trials. Current clinical guidelines, in absence of such clinical trials, 
neglect experimental and mechanistic data and provide generic recommendations only. 
20 
Oral antidiabetic drugs in post-MI remodeling 
Introduction: 
Heart Failure and Diabetes - a reciprocal relation 
The prevalence of diabetes mellitus is rapidly growing due to lifestyle and the aging 
population. Cardiovascular complications are the leading cause of diabetes-related 
morbidity and mortality. First, because diabetes is associated with other cardiovascular 
risk factors such as hypertension, dyslipidemia, but most importantly because diabetes 
leads to accelerated atherosclerosis, involving all large arterial beds: carotid, aorta, 
femoral, and the coronary arteries 1 • Coronary artery disease (CAD) is the leading 
cause for heart failure 2, either due to sustained ischemia or via myocardial infarction 
(MI), followed by a process of myocardial remodeling, in the end resulting in heart 






















Figure 1 Overview of the interaction between diabetes and heart failure 
Diabetic patients have a higher risk for developing heart failure, and apart from 
this, heart failure patients with diabetes have worse prognosis compared to heart failure 
patients without diabetes, as reported in numerous reports 3-5_ Furthermore, heart 
failure itself also bears an increased risk for new onset diabetes 6• 7, so that diabetes and 
heart failure have a reciprocal relation. Despite availability of effective treatments, 
heart failure remains one of the most common causes of death and health care 
2 1  
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expenditure. Therefore, novel therapies to reduce (post-Ml) cardiac remodeling and 
subsequent heart failure are urgently needed, and this need is particularly strong in 
diabetic patients. Currently, a wide array of oral antidiabctic agents is available which 
have primarily been evaluated for their glucose lowering capacity. However, recently 
there have been several reports questioning whether all these agents are safe in patients 
with risk for or established cardiovascular disease. Some drugs have been fiercely 
under debate because of safety concerns and increased risk for cardiovascular 
outcomes, like rosiglitazone 8• There are no prospective studies comparing the 
cardioprotective effects between different oral antidiabetic agents. We herein provide 
an overview of available experimental data of oral antidiabetic agents with respect to 
their cardiospecific effects, and postulate that these effects could be of help in choosing 
a therapeutic regimen in diabetic patients with concomitant cardiovascular disease, and 
specifically heart failure. 
Heart Failure and anti-diabetic medication 
Anti-diabetic medications arc primarily aimed to lower blood glucose levels. There are 
five classical types of anti-diabetic drugs: biguanides, sulfonylurca derivatives, 
mcglitinidcs, thiazolidinediones, and a-glucosidase inhibitors. Recently, novel 
compounds for diabetic treatment have been introduced on the market: the incrctin 
mimetic drugs (GLP-1 analogues), the dipeptidyl peptidase (DPP-4) inhibitors, the 
(dual) peroxisome proliferator-activated receptors (PPAR) agonists, and the amylin 
mimetic drugs 9• All drugs have established glucose lowering effects, and based on 
experience, tolerability, safety profile and price, they are indicated for type 2 diabetes 
as described in the guidelines 1 0• 
Recent published data from a meta-analysis has suggested that metformin 
improves clinical outcome and reduces all-cause mortality when compared to other 
treatments in patients suffering from both heart failure and diabetes 1 1 • 1 2• From these 
data, the suggestion arises that some oral anti-diabetic agents may exert superior 
cardioprotection over others. Given the comparable effects on blood glucose that most 
oral anti-diabetics share, it is unlikely that these differences arc simply explained by 
better glycemic control. However, mechanistic studies with different oral anti-diabetic 
agents primarily addressed the glycometabolic mechanisms of these compounds, while 
direct effects on other organs, including the heart have not been given much emphasis 
herein. 
In the current paper, we focus on the cardiospecific effects of the most 
commonly subscribed anti-diabetic agents on diabetes and heart failure and to compare 
these with the data available for the newer compounds. 
22 
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Classical medication 
Metformin and cardiovascular effects 
Metformin is the only drug belonging to the biguanides class and is currently utilized 
as first line anti-diabetic agent in most parts of the world. It decreases blood glucose 
levels by enhancing insulin sensitivity involving two major mechanisms: first, by an 
increased peripheral uptake of glucose (mainly skeletal muscles) in the presence of 
insulin, and second by a decreased hepatic glucose output through suppression of 
gluconeogenesis while lowering plasma insulin concentrations 1 3. Compared to other 
anti-diabetic medication, the use of metformin also includes ancillary, non­
hypoglycemic effects, such as improving both serum lipid profile and fibrinolytic 
activity 9• In addition, metformin has been shown to have effects that mimic caloric 
restriction, i.e. less body weight gain 14, and thus appears to be the drug of choice in 
obese patients. Clinical observations suggest that metformin might have direct 
cardioprotective effects independent of its glucose-lowering action: patients with type 
2 diabetes treated with metformin had a lower risk of all-cause mortality and 
myocardial infarction compared to other anti-diabetic medication 1 5• 1 6• Recent 
experimental data suggest possible mechanisms for metformins' cardioprotective 
effects, including reduction of myocardial ischemia-reperfusion injury as well as 
attenuated fibrosis and cardiac remodeling, e.g. in post-MI remodeling. 
Metformin limits myocardial ischemia-reperfusion injury (Table 1) 
Substantial evidence from experimental research demonstrates that metformin is 
beneficial in protecting the heart from ischemia-reperfusion injury. For example, in an 
isolated working rat heart model, low dose metformin was found to increase coronary 
blood flow before ischemia and during reperfusion, which was associated with 
improved cardiac function 17• Furthermore, another study demonstrated that a single 
oral dose of metformin (250 mg/kg body weight), administrated 24 hours before 
coronary occlusion, significantly reduced infarct size in a rat Langendorff-perfused 
heart. Interestingly, 2 hours after metformin administration an approximately two-fold 
increase in AMPK-a2 activity was observed 
18• AMPK-a2 is a protein necessary for the 
maintenance of myocardial energy homeostasis during ischemia 1 9• The metformin­
induced decrease in infarct size in rats was reproduced in a murine myocardial 
ischemia-reperfusion injury model. In this study, metformin administration (125 µg/kg; 
intraperitoneal injection) before the ischemic period decreased myocardial reperfusion 
injury in mice, associated with concomitant activation of AMPK and endothelial nitric 
oxide synthase ( eNOS) phosphorylation, which both appear to be crucial for limiting 
infarct size 20• Further evidence for metformins' cardioprotective properties upon 
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ischcmia stems from a study in both isolated perfused Wistar and diabetic Goto­
Kakizaki rat hearts. Here, coronary perfusion with metformin (50 µmol/L in the 
pcrfusate during the first 15 minutes of repcrfusion) reduced infarct size through Akt­
mcdiatcd inhibition of mitochondrial permeability transition pore opening 2 1 . In 
contrast, the cellular mechanism of cardioprotection by AMPK activation was not 
confirmed by Bhamra ct al 2 1 • Possible factors accounting for the discrepancies in 
findings may be related to different dose utilized in this study. An identical, infarct size 
limiting effect was later confirmed by other studies 22• 23. However, further support for 
mctformins' effect on reducing infarct-size is evident from a study in type 2 diabetic 
rats where oral metformin administration (200 mg/kg/day) led to significant reduction 
of infarct size compared to controls 24. Altogether, these studies offer insights into the 
cardioprotective effect of metformin in limiting myocardial ischcmia-rcpcrfusion 
injury by mechanisms entailing an increased AMPK activity and eNOS 
phosphorylation, leading to reduced myocardial infarct size and improved cardiac 
function. 
The effect of metformin on post-infarct remodeling and heart failure (Table 1) 
Importantly, the cardioprotective benefits of metformin are not limited to models of 
myocardial reperfusion injury but further extend to murine, rat and dog models of post­
myocardial infarction where mctformin treatment consistently ameliorated long-term 
cardiac remodeling. First, in a murine model of permanent left coronary artery 
occlusion metformin, administered to mice before ischemia and then daily for 4 weeks 
( 1 25 µg/kg; i.p. injections), improved 4-week survival from 30 to 44% 25• The 
underlying factors prolonging survival upon metformin administration appear to be 
associated with improved cardiac function as treated mice displayed preserved LV 
dimensions and LV ejection fraction at 4 weeks. In this model AMPK, eNOS 
phosphorylation and increased peroxisomc proliferator-activated receptor-gamma co­
activator (PGC)-1 alpha expression appear to be central players in metformins ' 
cardioprotcctivc effects. Importantly, AMPK, cNOS and PGC- l alpha are all regulators 
of cellular energy metabolism. 
The metformin-induced improvements in L V ejection fraction were confirmed 
in rat studies using myocardial infarction after permanent coronary ligation 26• 27• 
Administration of metformin (250mg/kg) during 12 weeks led to significant reductions 
in infarct size and left ventricular dilatation 26. Further, metformin treatment for 4 
weeks ( IO0mg/kg) significantly improved cardiac function ( increased L V systolic 
pressure, increased LV ejection fraction and decreased LV end diastolic diameter) 27• 
The beneficial effects of metformin in these rat studies were not only associated with 
the previously observed increases in AMPK and cNOS phosphorylation, but also with 
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a reduction in plasma insulin which may contribute to the cardioprotective effects of 
metformin. 
In addition, metformin also reduces myocardial fibrosis by reducing key fibrotic 
factors, including transforming growth factor (TGF)-Pl ,  basic fibroblast growth factor 
(bFGF), and tumor necrosis factor (1NF)-alpha levels in the circulation and/or the 
myocardium 27• Similarly, anti-fibrotic effects of metformin were also observed in 
other experimental heart failure models, including a dog model of rapid pacing 28 and 
murine pressure overload models, where a decreased expression of TGF-Pl was 
observed 29• 
Additionally, metformin has also been shown to attenuate the development of 
diabetic cardiomyopathy in diabetic mice via activation of AMPK 30• 
However, in contrast to the earlier observations in post-MI models, metformin 
had no effects on cardiac structure and function, and did not activate AMPK, in a 
volume-overload-induced heart failure model 3 1 • These results suggest that the 
protective effects may not be universal to all forms of heart failure. 
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Figure 2 Metfonnin activates AMPK phosphorylation, regulates cellular glucose signaling pathways, 




Taken together, convincing evidence has accumulated demonstrating that 
metformin ameliorates cardiac remodeling in different models of heart failure in 
several species, The underlying mechanisms appear to be related to improved substrate 
sensing mechanisms, such as increased AMPK activation and eNOS phosphorylation 
(as showed in Figure 2), as well as decreases activation of fibrosis-inducing players, 
such as reduced TGF-Pl .  
Sulfonylurea derivatives and the cardiovascular system 
Sulfonylurea derivatives are the first class widely used oral anti-hyperglycemic 
medication and they have been used for the treatment of type 2 diabetes mellitus for 
nearly half a century. Sulfonylurea derivatives are insulin secretagogues with a 
hypoglycemic potency which is directly related to baseline plasma glucose values 33• 
Further, the cellular mechanism of sulfonylurea derivatives is triggering insulin 
secretion by closing the ATP-dependent potassium channels in the pancreatic beta cell 
membrane (Figure 3). KATP channels have been identified not only in pancreatic P-cells, 
but also in neuronal cells, skeletal muscle, vascular and nonvascular smooth muscle 
cells 34• 
Figure 3. Targets or action or sulfonylurea derivatives in the pancreatic beta-cell and the 
cardiomyocyte. Sulfonylurea drugs inhibit KATP channels and prevent K
+ efflux through the channel pore, 
leading to membrane depolarization and opening of voltage-sensitive Ca2+ channels, which allows influx of 
calcium into the cell. Ca2+ influx induces insulin release in pancreatic beta-cell and increased contractility, 
ATP use, and action potential duration in the cardiomyocyte. Adapted and modified from 35• 
26 
Oral antidiabetic drugs in post-M I  remodeling 
Cardiac and vascular sulfonylurea receptors have been shown to have a different 
structure from their pancreatic analogue 35. KATP channels are reported to play a 
protective effect in the ischemic myocardium, regulating the coronary blood flow and 
protect cardiovascular cells from ischemia/reperfusion injury 36• In the healthy heart, 
blockade of KATr channels by sulfonylurea derivatives have been reported to reduce 
resting myocardial blood flow by 20% in a dog model 37• During ischemia, 
sulfonylurea derivatives may inhibit the cell hyperpolarization that protects the cell by Ill 
attenuating calcium accumulation 35 (Figure 3). Thus, from experimental data it seems a 
that inhibition of cardiovascular KATr channels by sulfonylurea derivatives may lead to 
increased cardiovascular risk 38. 
Sulfonylurea derivatives on myocardial ischemia-reperfusion injury (Table 1) 
Studies elucidating the effect of sulfonylurea derivatives on myocardial ischemia­
reperfusion injury have shown contradictory results, and it is challenging to put data 
into perspective. For example, glibenclamide, the second generation and widely 
prescribed anti-diabetic drug of this class, was first shown to have beneficial actions on 
myocardial ischemia-reperfusion injury, including a significantly improved functional 
recovery at 45 min in the reperfusion period and decreased cardiac lactate 
accumulation when administered as pre-treatment, although only at very high dose (50 
µM) 39. In contrast to the protective effects observed in the first study, glibenclamide 
prolonged recovery time from ischemia in another study using isolated hearts 40• 
However, despite the increased recovery time from ischemia in the latter study, 
cardioprotective effects including a significantly improved ischemia-induced cardiac 
functional loss as well as ischemia-induced intracellular acidosis were reported by 
Legtenberg et al 41 , thus suggesting sulfonylurea-induced cardiac-protection by 
glibenclamide. This was associated with a decrease in coronary blood flow, which was 
by another study in isolated perfused rat hearts that were treated with glibenclamide 
(3x 10-8mol/L) and glimepiride ( I  x l0-7 mol/L), both leading to significant reduction in 
coronary perfusion flow upon reperfusion. Moreover, at 30 minutes of reperfusion in 
this study, glibenclamide induced a significant increase in left ventricular end-diastolic 
pressure and significant decreases in left ventricular systolic pressure, left ventricular 
developed pressure, and the maximum first derivative of left ventricular pressure, while 
glimepiride induced a significant decreases in left ventricular developed pressure and 
the maximum first derivative of left ventricular pressure, suggesting that the effects of 
both drugs on the cardiac function was differential by both sulfonylurea derivatives 42• 
Interestingly, the cardio-protective effect of glibenclamide is, most likely, not 
attributable to myocardial KATP channel blockade, as glibenclamide preserved pH but 
not ATP levels during ischemia while it was indicated that the cardioprotective effect 
of glibenclamide may be explained by inhibition of glycolysis. 41  
27 
Chapter 2 
Unlike glibenclamide, the beta-cell selective sulfonylurca (R)-ACX does not 
aggravate cardiac ischemia-reperfusion damage as shown in a study using the isolated 
guinea pig model 43• Collectively, the effects of sulfonylurea derivatives on cardiac 
ischemia-reperfusion injury are still debated. Altogether the current data available 
describing the effects of sulfonylurea derivatives on cardiac ischcmia-reperfusion 
injury are not conclusive more research is needed herein for clarification. 
Sulfonylurea derivatives on post-Ml remodeling (Table 1) 
Little information is currently available describing the cardiovascular effects of 
sulfonylurca derivatives on post-MI remodeling and heart failure, herein only a few 
long-term studies have been performed. Altogether these studies suggest that there is 
significant discrepancy in the effects of sulfonylurea derivatives. 
For example, seven day post-MI treatment with glimepiride in rats did not 
reduce scar thinning and L V hypertrophy, while it inhibited L V dilatation, which is a 
key contributing mechanism in the development of heart failure 44. However, further 
studies then showed that glibenclamide abolished the cardioprotective effects of KATP 
channels activation, which altogether makes it difficult to put the effects of 
sulfonylurea derivatives into perspective. As Lee et al. reported, in a post-Ml 
remodeling model, a 4 week treatment with KATP channels agonists significantly 
attenuated cardiomyocyte hypertrophy and increased phosphorylated p70S6 kinase 
expression, which is a key trigger of protein synthesis for hypertrophic changes. 
However, when treated with glibenclamide, the antagonist of KATP channels, these 
protective effects were abolished 4547. 
Altogether this demonstrates that different sulfonylurea derivatives have 
generated differential effects in experimental cardiac remodeling models. Clearly, more 
research is warranted to elucidate specific cardiovascular effects of this class of drugs 
that is widely used in clinical practice, to gain better understanding of their clinical 
utility and safety. 
Thiazolidinediones and cardiovascular system 
Thiazolidinediones (TZDs), also known as "glitazones," selectively bind to peroxisome 
prolifcrator-activated receptor-y (PPAR-y), which is expressed predominantly in 
adipose tissue, vasculature, cardiac and skeletal muscle, and the liver, and is involved 
in transcription of genes regulating glucose and fat metabolism 48-50• TZDs improve 
insulin sensitivity and glucose uptake in skeletal muscle by increasing glucose 
transportcr-4 (GLUT-4) gene expression 5 1 • Moreover, TZDs reduce circulating fatty 
acid concentrations resulting in increased glucose utilization and decrease 
gluconeogenesis 51 •53_ Of particular interest for this review are the effects of TDZs on 
the cardiovascular system. A large body of evidence demonstrates that TZDs are 
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beneficial in improving cardiovascular risk by their favorable effects on lipid 
metabolism and the vascular endothelium 54. 
Thiazolidinediones and myocardial ischemia-reperfusion injury (Table 1) 
A number of experimental studies have been performed to investigate the protective 
effect of TZDs on myocardial ischemia-reperfusion injury. Herein, a large variety of 
different TZDs have been utilized, all consistently showing protective effects against 
myocardial ischemia-reperfusion injury. 
The protective effect of TZDs on myocardial ischemia-reperfusion injury was 
first shown in 2001 by Yue et al 55• The authors demonstrated that the PPAR-y agonist 
rosiglitazone (3 mg/kg/day) reduced myocardial infarction by 37% and improved 
contractile dysfunction after a 30 min of coronary ligation followed by 24 hours 
reperfusion. Moreover, pretreatment with rosiglitazone (3 mg/kg/day) for 7 days 
further reduced infarct size and also resulted in significant improvement of left 
ventricular systolic pressure and contractility 55• The reduction of infarct size by 
another TZD, pioglitazone, was then confirmed in a rat model of regional myocardial 
ischemia and reperfusion by Wayman and Ito 56• 57. Further evidence for the infarct­
size limiting effect of TZDs stems from a study employing a canine model of acute 
myocardial infarction utilizing troglitazone 58. ln this study it was shown that the 
cardioprotective of troglitazone was associated with an attenuated expression of 
connexin43, which has a crucial role in the synchronized contraction of the heart, in the 
border zone of the infarct. Moreover, administration of pioglitazone prior to ischemia 
reduced infarct size by 20% in male Sprague-Dawley (SD) rats 59. The authors 
suggested that the PBK and P42/44MAPK pathway may be the underlying mechanism 
herein as these two pathways showed to regulate the survival of the cardiomyocytes. A 
similar molecular mechanism was described in myocardial ischemia-reperfusion study 
( I hour of myocardial ischemia followed by 1 hour of reperfusion) in SD rat hearts 
after 7 days of pretreatment with rosiglitazone (3 mg/kg/day) 60• The rosiglitazone­
treated group displayed a significantly reduced infarct size with concomitant inhibition 
of p42/44 MAPK 60. 
Other mechanisms that have been postulated to mediate the protective effects of 
TZDs on myocardial ischemia-reperfusion injury include: decreased cardiomyocyte 
apoptosis 61 , increased phosphorylation of Akt, p42/44 MAPK and eNOS, and 
inhibition of Bax activation 62-65. For example, pioglitazone significantly improved 
heart rate and contractility (dP/dtmax) at 1 and 30 minutes after reperfusion in rats, 
which was associated with Akt phosphorylation 62• Interestingly, pioglitazone has been 
shown to inhibit cardiomyocyte apoptosis and inhibiting MMP-2 6 1 , reduce 
mitochondrial ultrastructural injury and membrane potential loss in the 
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ischemic/reperfused SD rat heart , thus indicating that its protective effects may be 
related to opening mitochondrial(ATP)-sensitive potassium channels 66· 67. 
In contrast, a subsequent study utilizing a rabbit ischemia-reperfusion model 
found that pioglitazone reduced infarct size by activation of PP AR-y, PB-kinase, Akt, 
and cNOS pathways, but not via opening the mitochondrial KATP channel 
68. Similar 
findings were observed in a mouse model 69' 70• Additionally, continuous infusion of 
rosiglitazone (0.5 mg/kg/h) significantly reduced infarct size by 20% in Wistar rat 
hearts after ischemia/reperfusion (30 minutes/4 hours) 7 1 . The authors of this study 
found that nuclear factor-kappa B (NFKB) phosphorylation was inhibited in the 
infusion group leading them to conclude that the underlying mechanism responsible for 
the reduction in infarct size constitutes the inhibition of the NFKB pathway 7 1 . 
Notably, activation of Akt appears essential for the cardioprotcctivc effects of 
TZDs. Administering rosiglitazone (3 mg/kg/day) to the Zucker Diabetic Fatty (ZDF) 
rat led to protection of the heart from ischemia-reperfusion myocardial injury by 
activating Akt 72 as similar findings as pioglitazone m non-diabetic 
· h ·a1 fu · · · 62 64 68-70 1sc cm1 rcper s1on mJury · · . 
To summarize, TZDs have consistently shown to decrease experimental 
myocardial ischemia-reperfusion injury and infarct size. Suggested mechanisms arc 
activation of Akt, eNOS, and p42/44 MAPK as the mediators of this beneficial effect. 
Thiazolidinediones and post-Ml remodeling (Table 1) 
The effects of TZDs on heart failure and left ventricular remodeling are more 
controversial. Mice treated with pioglitazone (3 mg/kg/day) for 4 weeks after large 
anterior Ml displayed significantly attenuated LV dilatation and dysfunction with 
pioglitazonc treatment, while L V end-diastolic pressure was decreased and L V dP/dt 
(max) was partially normalized 73. These improvements were associated with a 
decrease in myocytc hypertrophy, interstitial fibrosis and a reduced expression of genes 
implicated in fibrotic and inflammatory pathways, such as TNF-alpha, TGF- (3 1 ,  and 
monocytc chemo-attractant protein-I 73. However, in a subsequent study, the same 
dose of rosiglitazone (3 mg/kg/day) did not modulate LV remodeling and rather 
increased mortality after 8 weeks post-MI in rats 74. In a further investigation in mice 
subjected to Ml  prior to the onset of treatment, pioglitazone (20 mg/kg) had no effect 
on LV remodeling, survival, metabolic parameters, inflammation, collagen deposition 
and endothelial function 75. In contrast, utilizing a rat model with rosiglitazone (3 
mg/kg/day) for 8 weeks, Geng et al. demonstrated a beneficial effect of rosiglitazone 
on post-MI L V remodeling, evidenced by improvement in LV dP/dt max and decreased 
collagen formation, partly by suppressing myocardial angiotcnsin II and aldosterone, 
while no effect on mortality was noted 76. However, adding to the flurry of data, Linz et 
al. reported that rosiglitazone exacerbated cardiac dysfunction in Sprague Dawley rats 
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with permanent ligation of the left coronary artery 77• In addition to these post-MI 
remodeling studies, an increase in myocyte size and atrial natriuretic factor was 
observed in pioglitazone treatment (3 mg/kg/day) for 4 weeks in a rat model of aortic 
banding 78• 
Taken together, there is clear evidence that TZDs are beneficial against 
myocardial ischemia-reperfusion injury. However the effects on post-MI remodeling 
are unclear. Differences in study design and dose regimen are most likely the 
underlying causes for discrepancies in findings between all these studies, and clearly 
careful future investigation is warranted to further clarify herein. 
New generation anti-diabetic drugs 
Glucagon-like peptide analogues and DPP-4 inhibitors 
Glucagon-like peptide-I (GLP-1) is secreted by entero-endocrine L-cells of the 
intestinal mucosa and released into the circulation in response to food intake. GLP-1 
analogues have been used for treatment of type 2 diabetes since it improves insulin 
secretion, P-cell proliferation and survival 79-8 1 • For these reasons, GLP-1 is an 
attractive target in the treatment of type 2 diabetes. However, targeting endogenous 
GLP is clinically impractical by itself as its half life is only a few minutes due to its 
rapid inactivation by the enzyme dipeptidyl peptidase-4 (DPP-4). Therefore, an 
analogue of GLP-1 appears more beneficial. Herein, exenatide (also known as 
Exendin-4) and liraglutide have already been approved by the FDA as GLP analogues 
to treat type 2 diabetes. An alternative approach for enhancing GLP-1 bio-availability 
and thus action involves the use of DPP-4 inhibitors (Figure 4). The DPP-4 inhibitors 
sitagliptin 82 and saxagliptin 83 have been approved by the FDA as treatment for type 2 
diabetic patients in the United States, while vildagliptin has been approved in Europe 
as anti-diabetic treatment 84• 
GLP-1 and the cardiovascular system 
GLP-1 receptors (GLP-IR) are expressed in various tissues outside the pancreas, and 
also in rodent and human heart and vascular tissue 85• The function of these receptors in 
heart and vasculature are under study. GLP-IR deficient mice have shown to exhibit 
increased L V thickness, impaired L V contractility and impaired L V diastolic function, 
compared to control mice 86, clearly indicating the importance of this receptor for the 
cardiovascular system. Moreover, in a clinical study, 3-day infusion of GLP-1 
improved LV function in patients after acute myocardial infarction 87• Thus, in addition 
to the effects on glucose metabolism, GLP-1 has been proven to exert cardiovascular 
effects 88• 




DPP-4 Inhibitor l l 
Intestine --+ r-Act-i-ve_G_L_P ___ 1_ ----+ 
GLP-1 metabol ite 
Inactive 
- - - . 
Figure 4 Secretion and metabolism of glucagon-Iike peptide-I (GLP-1 ). Following ingestion of a meal, 
GLP-1 is released from the intestine in its active form (7-36) in plasma, which is rapidly degraded to 
the inactive form (9-36) by the enzyme dipeptidyl peptidase-4 (DPP-4). Incretin therapy can increase 
available GLP-1 activity by inhibiting its enzymatic degradation using DPP-4 inhibitor to prolong the 
activitv ofGLP-1 .  
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Figure S. GLP-lR-dependent intracellular signal transduction pathways in the cardiomyocyte. Activation of 
the GLP-lR leads to a reduction in apoptosis and increase in glucose u�take. ROS, Reactive oxygen species. AC, Adenylate cyclase. Reprinted with permission from the publisher. 
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GLP-1 limits myocardial ischaemia-reperfusion injury (Table 2) 
Acute GLP- I infusion studies in rodents showed, for the most part, consistent 
beneficial cardiac effects entailing a decrease in infarct size and improved L V function. 
For example, ischemia/reperfusion experiments in rats showed that GLP- I 
administration prior to ischemia leads to smaller infarct size in the isolated heart 90•92• 
Another ischemia-reperfusion study showed that only the GLP- 1 analogue exendin-4, 
but not GLP- I(9-36) amide exerts infarct-limiting action, while both of them improved 
LV performance 93• This was partially confirmed by Ossum, et al 94, who studied 30 
minutes low-flow ischemia and 30 minutes reperfusion. GLP-I  enhanced recovery with 
significant improvements in L V end-diastolic pressure and L V developed pressure 
after ischemia, increased LV function, myocardial glucose uptake, and GLUT-I and 
GLUT-4 translocation during reperfusion, in association with increased p38 MAPK 
activity and enhanced NO production in isolated rat hearts 95 (Figure 5). Another study 
then demonstrated that both GLP- I and its metabolite GLP- I (9-36) exerted cardiac and 
vascular protective effects in isolated mouse hearts after ischemia-reperfusion injury as 
demonstrated by increased functional recovery, glucose uptake, cAMP and cGMP 
release, left ventricular developed pressure, and coronary flow 96• However, a study 
with liraglutide, a long-acting GLP-I analogue, showed no effect on infarct size and 
hemodynamic parameters in a porcine model 97• Then, applying liraglutide to both 
healthy and diabetic mice showed higher survival in treated mice with concomitant 
improved cardiac output. This was associated with the expression and activity of 
cardioprotective genes in the mouse heart, including Akt, GSK-3P, PPARbeta-delta, 
Nrf-2, and HO-I 98. Exenatide was found to play a beneficial effect on ischemia­
reperfusion in both an adult rat 99 and porcine model, associated with a higher Akt and 
Bcl-2 phosphorylation and lower active caspase-3 expression 1 00 (Figures 5). Fusion of 
GLP-1 to human transferrin (GLP- I -Tf) significantly reduced the infarct size and 
apoptotic index of the cardiomyocytes. Wall motion abnormality and ejection fraction 
was significantly improved in the post-ischemic group relative to the control group 
1 0 1 • 
The effect of GLP-1 on post-infarct remodeling and heart failure 
Only few chronic studies have addressed the effects of GLP- I on cardiac function in 
post-MI remodeling. A chronic (3 month) infusion study showed that GLP- I improved 
LV systolic function and prolonged survival in spontaneously hypertensive rats by 
increasing myocardial glucose uptake and reducing myocyte apoptosis 1 02• Treatment 
either with GLP-I or the exenatide analogue AC3 I 74 also demonstrated promising 
cardioprotective effects, including improved L VEF, LV end-diastolic pressure, and 
cardiac dimensions in a rat MI model 1 03• Further, recombinant GLP-- I increased 
myocardial insulin sensitivity, glucose uptake and improves left ventricular 
performance which was associated with significant increases in L V hemodynamic 
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parameters and systemic vascular resistance in conscious dogs with pacing-induced 
dilated cardiomyopathy 1 04• In a type l diabetic rat model, 14 day infusion of GLP-1 
analogue cxcndin-4 showed an early protection of cardiac remodeling 105• 
Dipeptidyl peptidase-4 inhibitors (Table 2) 
Two acute studies addressed the role of DPP4 inhibitors in cardioprotection. A study 
with the DPP-4 inhibitor PFK275-055 (a vildagliptin-analoguc) showed a reduced 
infarct size with activation of the cardioprotective RISK (reperfusion-induced salvage 
kinase) pathway in pre-diabetic rats 106, whereas a study with the DPP-4 inhibitor 
sitagliptin showed that infarct size or short-term cardiac function were not affected by 
treatment 107• This result was in line with another study which also showed that 
sitagliptin was associated with a reduction of infarct size 65. However, data on long­
term studies of DPP-4 inhibitor on post-MI remodeling arc limited. Administration of 
vildagliptin for 12 weeks had no beneficial effects on parameters of LV function or 
cardiac gene expression in nondiabctic rats after coronary artery ligation and 
development of ischemic cardiac remodeling 1 08• Further studies are needed. 
Translation to clinical practice 
Over the years, several clinical studies and registries evaluated the safety and efficacy 
of oral anti-diabetic drugs on cardiovascular risk (Table 3). In general, glucose 
lowering regimens are associated with less diabetic complications, as shown by the 
multiccntcr UKPDS study that presented data on long-term oral anti-diabetic agents or 
insulin treatment and the associated reduction in development of microvascular 
complications in newly diagnosed type 2 diabetes mellitus 109• It has become apparent 
that mctformin is the superior oral anti -diabetic drugs in preventing cardiovascular 
events 15 • Compared to other anti-diabetic drugs, metformin is not only associated with 
a reduction of morbidity in patients with heart failure 1 10 but also with a lesser 
cardiovascular hospitalization and all cause mortality 1 1 1 • Both clinical and 
experimental studies have suggested that metformin may play a beneficial role in the 
cardiovascular system and could be a novel treatment for patients with myocardial 
infarction or heart failure, especially for pre-diabetic and obese patients. 
Contrasting to metformins ' promising results, clinical studies with 
sulfonylurea derivatives have produced conflicting results. A large US multicenter trial, 
the University Group Diabetes Program (UGDP), was the first to report that 
tolbutamide treatment caused adverse cardiovascular effects in human patients 1 12• 
Although several experimental studies have suggested that sulfonylurea derivatives 
may exert a harmful effect on ischemic-rcperfusion injury, as reviewed above, the 
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UKDPS study did not observe a higher risk of myocardial infarction in patients who 
received sulfonylurea derivatives compared with those treated with insulin alone 109• 
Higher mortality was found on a combined sulfonylurea derivative and metformin 
regimen in patients with coronary artery disease compared with monotherapy with 
sulfonylurea derivatives 9• Moreover, some clinical studies showed a decreased 
incidence of cardiovascular complications in patients on sulfonylurea derivatives 52• 
Collectively, the benefits and harms of sulfonylurea derivatives on the cardiovascular 
system in clinical practice remain debatable and further investigations need to be 
performed. Cautious use of sulfonylurea derivatives in patients post-MI or with heart 
failure seems to be indicated. 
Although experimental findings suggest a possible benefit of TZDs in 
cardiovascular protection, clinical data on cardiovascular outcome are questionable. 
Three meta-analyses indicated an increase in the incidence of MI and heart failure for 
TZDs (in particular rosiglitazone, to a lesser pioglitazone) compared to placebo 1 13- 1 15_ 
TZDs were associated with increased risk of hospital admission for heart failure but 
were associated with reduced all cause mortality 1 2• The open label trial Rosiglitazone 
Evaluated for Cardiac Outcomes and Regulation of glycemic in Diabetes (RECORD) 
did not observe any effects of rosiglitazone on all-cause mortality; however, a higher 
frequency of heart failure was found in this study 1 16• 1 1 7• In a recent clinical trial, 
Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction 
Prospective Evaluation (PERISCOPE), pioglitazone treatment led to a significantly 
decreased rate of progression of coronary atherosclerosis in diabetic patients with 
coronary artery disease 1 18• To date, the understanding of TZDs on cardiovascular risk 
and mortality is still limited; partially due to incomplete knowledge of the underlying 
molecular mechanisms, that are expected to be very complex for agonists of the 
transcription factor PPAR-y. 
Newer anti-diabetic agents, including GLP-1 and its analogues, have been 
reported to play a protective role on the cardiovascular system in experimental models. 
Since DPP-4 inhibitors increase the endogenous level of GLP-1 by inhibiting its 
degradation, DPP-4 inhibitors are also considered to have similar effects as GLP-1 and 
its analogues. However, these medications have been used only for a few years and no 
data on large clinical trial are yet available, more long-term studies on cardiovascular 
effects are ongoing. 
In conclusion, based on the literature review mentioned above, metformin 
should be strongly recommended for diabetic patients with concomitant cardiac disease. 
Metformin exerts beneficial effects on the cardiovascular system, both in experimental 
studies as well as in (post-hoc) clinical observations. Data on sulfonylurea derivatives 
and TZDs have shown controversial results; their use in diabetic patients with 
cardiovascular disease is under debate and needs further study. In current guidelines, 
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these classes of drugs are recommended if patients remain hyperglycemic despite 
metformin use, and no remark with respect to cardiac disease or condition is made. We 
believe clinicians should use these drugs cautiously. For the more recently developed 
anti-diabetic agents, the experimental data are promising. However, based on the 
experiences with sulfonylurea derivatives and TZDs, clinical studies are needed to 
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Table 2 Effects of new antidiabetic agents in non-diabetic post-MI animal models. 
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t LVEF 1 02 
I myocardial glucose uptake 96, 9' 
t cAMP and cGMP release 91 
t survival 99 
t Akt, GSK3 J3 ,  PPAR- J3 or PPAR- 6 ,  Nrf-2, and HO- I 99 
' apoptosis 10 1 . 1 02 
+ Infarct size 66• 107 
t RISK pathway 107 
No effect on infarct size 108 
I mortality 108 
t HO-I ,  ANP, and pGSK-3 J3 proteins 108 
Chronic studies 
I myocyte apoptosis 103 
j LVEDD !OS 
t LV function 103• 1 04 
t LVEF 1 04 
t myocardial glucose uptake ios 
t survival 103 
t L V dP/dt stroke volume and cardiac output !OS 
No beneficial effects ofDPP-4 inhibition on 
long-term remodeling 109 
LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; ANP, atrial natriuretic peptide; GSK3P, Glycogen synthase 
kinase 3 p; PPAR-P or PPAR-o, peroxisome proliferator-activated receptor beta or delta; Nrf-2, Nuclear factor (erythroid-derived 2)-like 2; HO- I ,  
Heme oxygenase- 1 .  
n 
















Main findings in clinical studies 
Reduction microvascular complications uo 
Decrease cardiovascular events 15 
Reduce morbidity in patients with heart failure 1 1 1  
Lesser cardiovascular hospitalization and all cause mortality 1 1 2  
UGDP- increase detrimental cardiovascular effects in patients 1 13 
UKPDS- no higher risk of myocardial infarction 1 10 
Sulfonylureas monotherapy had lower mortality than combination therapy 9 
Reduction in incidence of cardiovascular complications in patient 52 
Increase in the incidence of myocardial infarction and heart failure 1 14-1 1 6  
Increased risk of hospital admission for heart failure but was associated with reduced all cause mortality 12 
RECORD-no increased all-cause mortality but increase heart failure 1 18 
PERISCOPE- decreased rate of progression of coronary atherosclerosis 1 19  
UGDP, University Group Diabetes Program; UKPDS, United Kingdom Prospective Diabetes Study; RECORD, trial of Rosiglitazone Evaluated 
for Cardiac Outcomes and Regulation of glycemic in Diabetes; PERISCOPE, trial of Pioglitazone Effect on Regression of Intravascular 
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Chapter 3 
Abstract 
Metformin is the first choice drug for the treatment of patients with diabetes, but its use 
is debated in patients with advanced cardiorenal disease. Epidemiological data suggest 
that metformin may reduce cardiac events, both in patients with and without heart 
failure. Experimental evidence suggests that metformin reduces cardiac 
ischemia/reperfusion injury. It is unknown whether metformin improves cardiac 
function (remodeling) in a long-term post-Ml remodeling model. We therefore studied 
male, non-diabetic, Sprague-Dawley rats that were either subjected to myocardial 
infarction (Ml) or sham operation. Animals were randomly allocated to treatment with 
normal water or metformin containing water (250mg/kg/day). At baseline, 6 weeks and 
1 2  weeks, metabolic parameters were analyzed and oral glucose tolerance tests (OGIT) 
were performed. Echocardiography and hemodynamic parameters were assessed 
twelve weeks after Ml. In the MI model, infarct size was significantly smaller after 1 2  
weeks metformin treatment (29.6_t3.2 % vs. 38.0±2.2%, p<0.05). Moreover, metformin 
resulted in less left ventricular dilatation (LVIDs: 6.0±0.4 vs. 7.6±0.6 mm, p<0.05) and 
preservation of left ventricular ejection fraction (65.8±3.7 % vs. 48.6±5.6 %, p<0.05) 
as compared to MI control. The improved cardiac function was associated with 
decreased ANP (Atrial Natriuretic Peptide) mRNA levels in the metformin-treated 
group (50% fold reduction compared to Ml, p<0.05). Insulin resistance did not occur 
during cardiac remodeling (as indicated by normal OGTT) and fasting glucose levels 
and the pattern of the OGTT were not affected by metformin. Molecular analyses 
suggested that altered AMPK phosphorylation status and low insulin levels mediate the 
salutary effects of metformin. Altogether our results indicate that metformin may have 
potential to attenuate heart failure development after myocardial infarction, in the 
absence of diabetes and independent of systemic glucose levels. 
Key words: Metformin, myocardial infarction, remodeling, heart failure, left 
ventricular function, diabetes. 
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Introduction 
The prevalence of patients with diabetes and heart failure (HF) is growing 
exponentially. Compared to HF patients without diabetes, diabetic HF patients have a 
poor prognosis and quality of life 1 ' 2• Moreover, diabetes is an established risk factor 
for incident episodes of HF 3. According to the HF guidelines metformin should be 
considered as a first-line agent in overweight HF patients with type 2 diabetes without 
significant renal dysfunction 4• This recommendation is based on clinical studies 
showing that metformin seems the only anti-diabetic agent without a harmful cardiac 
effect in diabetic HF patients 5• 
Metforrnin decreases blood glucose by enhancing insulin sensitivity, inducing 
greater peripheral uptake of glucose, and decreasing hepatic glucose output while 
lowering plasma insulin concentrations 6' 7• The cardioprotective effects of metforrnin 
can, however, not be attributed to the glucose lowering effects alone 8• Recent 
experimental studies suggested ancillary potential mechanisms. More specifically, the 
protective effects may be conferred via the AMP-activated protein kinase (AMPK) 
pathway 8-1 3, which is activated by metforrnin. Especially, in ischernia/reperfusion (I/R) 
models, metformin was shown to decrease the cardiomyocyte apoptosis 1 1 • 14, to 
improve endothelial function by increasing NO production 8• 1 1 • 1 5, to maintain 
myocardial energy production during ischernia 16, and to affect lipid metabolism 1 7- 19• 
Clinical studies show that metforrnin may reduce plasma dipeptidyl peptidase-4 
(DPP-4) activity and increase circulating levels of glucagon-like peptide I (GLP-1) 
which is an incretin hormone that has protective effects on the heart and the vasculature 
20-22. Experimental studies employing a pressure-overload model in mice an_d a 
pacing-model in dogs showed that metformin attenuates cardiac fibrosis by inhibiting 
collagen synthesis 1 1 ' 13 • 
These experimental studies strongly suggest that metforrnin reduces I/R injury. 
However, little evidence is available to support the use of metformin in chronic cardiac 
remodeling, e.g. after MI and in HF. 
To further investigate the role of metforrnin in HF we conducted a long term study 
to determine the effects of metforrnin on cardiac function and metabolic parameters in 
a post-MI rat model. 
Methods 
Design of the Study 
Sprague Dawley rats (weight 250-260g, Harlan, The Netherlands) were randomly 




The sham procedure was identical to the Ml group except that the ligation was not tied 
23. Two days before surgery, rats were fed metformin containing water (250mg/kg/day) 
or normal water, and this was continued for a period of 1 2  weeks, rendering four 
experimental groups: sham (N-7), sham+metformin (N=7), Ml (N=8), and 
MI+metformin (N=9). The animals were further fed ad-libitum with a standard rat diet, 
and housed in groups of 4-5 rats under a 1 2-hour light: dark cycle. All animals received 
standard care and the experimental protocol was reviewed and approved by the local 
Animal Ethical Committee of the University Medical Centre Groningen. 
At baseline, week 6 and week 12, an oral glucose tolerance test (OGTT) was 
performed. At week 12, cardiac function was determined by echocardiography. After 
1 2  weeks the rats were sacrificed after measuring invasive hemodynamic parameters, 
and the hearts were rapidly excised, weighed, and prepared for histochemistry and 
molecular analysis. 
Oral glucose tolerance test 
An OGTT was performed in non-anesthetized rats. After 1 6-hour fasting, glucose (2 
g/kg as a 50% solution) was given orally to the animal. Blood was obtained from the 
tail to measure glucose levels at several time points: 0, 5, 15, 30, 60, and 120 minutes 
after the glucose administration. Glucose levels were measured with a blood glucose 
monitor (Accu-Check®, Roche, Germany). 
Echocardiographic measurement 
Echocardiographic measurements were performed by an individual blinded researcher 
to the treatment groups. Rats were anaesthetized with 2.5 % isoflurane in a gas mixture 
of N20/02. The M-mode and 20 echocardiography images were obtained with a 
high-resolution system (Vivid 7, GE, Healthcare, and Chalfont St Giles, UK), using a 
1 0  MHz transducer. Diastolic and systolic measurements of LV dimensions (LVIDd, 
LVIDs), as well as measurements of the thickness of the interventricular septum (IVSs, 
IVSd) and posterior wall (LVPWs, LVPWd) were recorded. LV fractional shortening 
(FS %) was calculated as FS= (LVIDd-LVIDs)/LVIDdx l 00¾. LY ejection fraction (EF 
%) was calculated using the Teichholz method of estimated LV volumes 24. 
Haemodynamic measurement 
Before sacrifice, rats were anesthetized and invasive hemodynamics were measured as 
described 25• Briefly, a microtip catheter with pressure transducer (2 Fr, Millar Instr. Inc, 
Houston, TX, USA) was inserted into the right carotid artery and advanced into the left 
ventricular cavity. After 5 minutes stabilization, the heart rate (HR), left ventricular 
end-systolic pressure (LVESP), end-diastolic pressures (LVEDP) and developed left 
ventricular pressure (dLVP-LVESP-LVEDP) were recorded. The parameters of the 
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maximal rates of increase and decrease in developed LV pressures (dP/dtmax and 
dP/dtmin) were determined. 
Procurement of heart tissue for infarct size, cardiomyocyte size and interstitial 
fibrosis measurement 
After sacrifice, hearts were rapidly excised and arrested in diastole in 2 M ice-cold KCI. 
The right ventricle and atria were removed. The basal and apical parts of the LV were 
snap-frozen in liquid nitrogen. A mid-papillary slice of the LV was fixed in 4% 
paraformaldehyde overnight and paraffin-embedded. The deparaffinized 3 µm sections 
were stained with picrosirius red/fast green, as described 26. The infarct size was 
calculated as percentage of the scar length to the total LV circumference. The images 
were obtained with a Leica microscope and analyzed using appropriate software 
(Image-pro plus, version 4.5.0.29). 
Furthermore, sections were stained with a Gomori's silver staining to allow 
visualization of the cardiomyocytes membranes. We measured cell size from 
transversally cut cardiomyocytes in the border zone of the infarcted area using image 
analysis software (Zeiss KS400, Germany). Finally, the collagen volume fraction was 
examined in sections of the left ventricular free wall, after excluding vessels. Tissue 
sections were stained with Masson's trichrome stain to evaluate the extent of interstitial 
fibrosis, modified from previously described methods 25. The area of stained tissue was 
calculated as a percentage of the total area within a field by using imagescope software. 
Biomolecular assays 
Arterial blood was collected with EDTA-coated centrifuge tubes. After centrifugation 
at 3000 rpm for 15  min at 4 °C the plasma was divided into different tubes and snap 
frozen in liquid nitrogen and stored for future additional analysis. Metformin was 
measured using high-performance liquid chromatography (HPLC) in the lab of 
Pharmacy of University Medical Centre Groningen. Insulin levels were measured at 12 
weeks after surgery using an ELISA kit (Rat/Mouse insulin 96-well plate assay, 
Millipore, MA, U.S.A.). The plasma active Glucagon-like peptide ! (GLP-1) and 
adiponectin levels were measured using the ELISA kits from Linco research and 
Millipore MA, U.S.A. Myocardial glycogen content was measured using the 
EnzyChrom™ Glycogen Assay Kit (BioAssay Systems, Hayward, CA, USA), 
according to manufacturer 's protocol. 
Real-time PCR 
Total RNA from the border zone tissue of infarction was extracted with TRizol reagent 
(lnvitrogen Corp., Carlsbad, CA, USA) and RNA concentrations were measured with a 




thereafter used as a template for quantitative real-time reverse-transcriptase-PCR 
(qRT-PCR) (25 ng/reaction). mRNA levels are expressed in relative units based on a 
standard curve obtained by a calibrator cDNA mixture. All measured mRNA 
expression levels were corrected for 36B4 reference gene expression. Primer sequences 
can be found in Table I .  
Table I .Primer sequences used in Real-Time PCR 
Gene 5'-3'Forward 5' -3 'Reverse 
ANP ATGGGCTCCTTCTCCATCAC TCTACCGGCATCTTCTCCTC 
eNOS GACTTTIAAGGAAGTAGCCAATGCA GTGAAGGCGACTATCCTGTATGGCTC 
Collagen I ACAGCGTAGCCTACATGG AAGTTCCGGTGTGACTCG 
Proco Hagen GAGGGCGAGTGCTGTCCTI GGTCCCTCGACTCCTATGACTTC 
36B4 GTTGCCTCAGTGCCTCACTC GCAGCCGCAAATGCAGATGG 
ANP:  atrial natriuretic peptide; eNOS: Endothelial nitric oxide synthase; Collagen l :col lagen type I ;  36B4: 
acidic ribosomal phosphoprotein PO. 
Western blot analysis 
Myocardial tissue samples (75 mg), taken from the area-at-risk portion of the LV, were 
homogenized in I ml RIPA buffer (50 mM Tris pH 8.0, I %  nonidet P40, 0.5% 
deoxycholate, 0. 1% SOS, 1 50  mM NaCl) containing phosphatase inhibitor cocktail I 
(Sigma), protease inhibitor (ROCHE) and I mM phenylmethylsulfonyl fluoride 
(PMSF). Protein concentrations were quantified with the DC protein assay (Bio-Rad 
Laboratories, Veenendaal, the Netherlands) with bovine albumin as a standard. Equal 
amounts of protein were loaded onto polyacrylamide-SDS gels and after 
electrophoreses, proteins were transferred to a PVDF membrane. The membrane was 
blocked I h with 5% non-fat milk in PBST and probed with primary antibodies 
overnight at 4°C. The following primary antibodies were used: Phospho-AMPKa 
Thr l 72 (1 :500, Cell Signaling Technology); AMPKa (1 : 1 000, Cell Signaling 
Technology); p-Akt Ser473 ( I :  1 000, Cell Signaling Technology); Akt ( I :  1 000, Cell 
Signaling Technology); Phospho-eEF2 Thr56 ( 1 : 1 000, Cell Signaling Technology); 
eEF2 ( I : 1 000, Cell Signaling Technology); Phospho-p70S6K Thr389 ( I : 1 000, B&D 
systems); p70S6K ( 1 : 1 000, B&D systems); AMPK a l  and AMPK a2 1 : 1 000, Cell 
Signaling Technology); GLUT4 ( I :  1 000, Cell Signaling Technology); Cleaved 
Casepase-3 ( I :  1 000, Cell Signaling Technology); GAP DH (I :20,000, Fitzgerald 
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Industries International, Acton, Mass). lmmunoblots were next processed with 
secondary antibodies for 1 hr at room temperature followed by ECL detection using an 
ECL+Plus chemiluminescence reagent kit (Amersham). 
Statistical Analysis 
All data are expressed as means ± standard errors of the mean (SEM). Differences 
among groups were tested by one-way analysis of variance (ANOVA) with a 2-sided 
Dunnett t-test as post-hoc test, taking the MI group as a comparator. Comparison 
between groups sham and sham+metformin was tested by independent t tests. P-values 
<0.05 were considered statistically significant. SPSS (PASW, Chicago, IL, USA) 
version 1 8.0 was used to perform all statistical analyses. 
Results 
The effect of metformin on metabolic parameters. 
To confirm that metformin was consumed by the rats and entered the blood stream, 
serum metformin levels were measured. In both treatment groups (sham+metformin 
and MI+metformin), the serum levels of the drug were around 3mg/L, while no 
metformin could be detected in non-treated groups (Fig. IA, upper panel). As 
metformin is an oral antihyperglycemic agent, that may lower the blood glucose levels, 
fasting glucose levels were determined and OGTis were performed. No differences 
were found in the fasting glucose levels between the groups at baseline, week 6 and 1 2  
after surgery (12 weeks results shown in Fig. IA, middle panel). Moreover, no 
differences could be identified in the OGTis at these intervals (Fig. IB), suggesting 
that glucose uptake from the plasma was not altered and that long term remodeling 
after Ml did not generate insulin resistance in these rats. Blood plasma insulin levels 
were also determined and were significantly decreased in both metformin-treated 
groups as compared to non-treated groups (Fig. IA, lower panel). Since glucose levels 
were unaltered, this suggests that metformin sensitized insulin responsiveness in 
metformin treated animals. Myocardial glycogen content in both metformin-treated 
groups was significantly decreased compared with non-treated groups (Fig. IC). We 
also observed a lower body weight gain in metformin treated animals (both sham and 
Ml) as compared to the untreated animals (Fig. 1D). Food intake was analyzed, but no 
consistent differences were observed in time and therefore this lower gain in weight did 
not appear to be linked to food intake ( data not shown). Therefore, we decided to 
analyze additional plasma parameters controlling metabolism. In particular active 
GLP- 1 and adiponectin plasma levels were determined by ELISA. No differences were, 
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Figure I .  Mctfonnin levels, glucose levels, insulin levels myocardial glycogen content and body weight 
gain at 1 2  weeks after M l  surgery. Panel I A, upper panel: serum metformin levels; middle panel: fasting 
glucose levels; lower panel: plasma insulin level. Panel I B: oral glucose tolerance tests were performed at 
baseline, 6 weeks and 12 weeks after M l  surgery. No significant differences were found among all  groups. 
Panel I C: Myocardial glycogen content. Panel I D: The use of metformin is associated with attenuated body 
weight gain. •p 0.05 vs. sham group; #P<0.05 vs. M l  group. 
Table 2 
Active GLP-1 (pM) 
Adiponectin (µg/mL) 





Sham+Met MI MI+Met 
5.65±0.33 5.75±0.21 5.58±0.27 
16. 1 8±0.74 15.45±0.55 14.93±0.58 
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Cardiac and hemodynamic parameters 
Infarct size was significantly smaller in the MI+metformin group as compared to the 
MI control group (MI+metformin 29.6±3.2% versus MI control 38.0±2.2%, P<0.05) 
(Table 3 & Figure 6B). As expected, MI caused significant reduction of blood pressure, 
LVESP, dP/dtmax and dP/dtmin, but no improvement was observed after a 12-weeks 
treatment with metformin. However, it is of note that sham-operated metformin-treated 
animals also had significantly lower blood pressure and LV pressure, possibly related 
to decreased oral (water, food) intake. The LVEDP was increased in the MI  group as 
compared to the sham group, and was slightly decreased in the MI+metformin group as 
compared to the MI group (Table 3). 
Table 3 Body weight, LV weight and body weight ratio, infarct size and hemodynamic 
parameters. 
Sham Sham+Met Ml Ml+Met 
BW baseline (g) 320±9 314±6 313±4 313±4 
BW 12week (g) 433±15 399±9 428±11 394±12 
LVW/BW 2.21±0.08 2.38±0.02 2.23±0.04 2.47±0.04# 
Infarct size (%) 0 0 38.0±2.2* 29.6±3.2*# 
Heart Rate (bpm) 303±8 273±8* 311±10 274±8# 
SBP (mmHg) 116±3 105±3* 105±3* 102±2 
DBP (mmHg) 79±3 71±3* 76±1* 70±2 
LVESP (mmHg) 117 ±3 106±3* 106±3* 104±2 
LVEDP (mmHg) 11±2 14±5 18±4 15±2 
dP/dtmax (mmHg/s) 7199±299 5444±264* 5836±390* 5166±166 
dP/dtmin (mmHg/s) -8399±553 -6496±524* -5516±669* -5488±197 
All values are means±SEM. 
*Indicates statistically significant difference compared to sham-operated rats (P<0.05) 
# Indicates statistically significant difference compared to MI control rats (P<0.05) 
BW=body weight; LVW:(eft ventricle weight; LVWNW=the ratio of left ventricular weight and body 
weight; bpm, beats per minute; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVESP, left 
ventricular end-systolic pressure; LVEDP, left ventricular end-diastolic pressure; dP/dtmax and dP/dtmin, 














Sham Sham+Met Ml  Ml+Met Sham Sham+Met Ml Ml+Met 
C D * 1 0  
1 0  * 
8 









Sham Sham+Met Ml Ml+Met Sham Sham+Met Ml Ml+Met 
E F 









Sham Sham+Met Ml Ml+Met Sham Sham+Met Ml Ml+Met 
Figure 2. Effects of mctformin on echocardiographic parameters. Panel A and Panel B: interventricular 
septum diameters (IVS) in diastole and systole, respectively; Panels C and D: left ventricular internal 
dimensions (LYID) in both diastole and systole, respectively; panel E: LY ejection fraction, and panel F: 
fractional shorten ing of the LY. *P<0.05 vs. sham group; #P<0.05 vs. Ml group.  
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The presence of MI was accompanied by wall thinning of the anterior wall 
(Figure 2A and B) as determined by echocardiography. Treatment with metformin 
significantly attenuated this wall thinning. Furthermore, 12 weeks after MI, severe LV 
dilatation was observed as shown by the increased LVIDd and LVIDs, and this resulted 
in lower FS and LVEF. Again, metformin significantly attenuated LV dilatation and 
partially prevented LV dysfunction (Figure 2C-F). 
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Figure 3. Quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR) was conducted 
and expression was measured of myocardial atrial natriuretic peptide (ANP; A), endothelial nitric oxide 
synthase (eNOS; 8), procollagen (C), and collagen I (D), respectively (mRNA corrected for 3684 mRNA 
level). The relative corrected values are shown for each group. *P<0.05 vs. sham group; #P<0.05 vs. M l  
group. 
3.3. Cardiac gene expression 
To assess the molecular changes induced by long-term metformin treatment, cardiac 
gene expression of ANP, endothelial nitric oxide synthase ( eNOS), procollagen and 
collagen I were measured by RT-PCR (Figure 3). The ANP mRNA level was 
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significantly increased after Ml compared to sham (P<0.05), but in metformin treated 
Ml animals this increase in AN P expression was significantly attenuated (Figure 3A). 
The eNOS mRNA level was markedly decreased in the Ml group as compared to sham, 
and metformin partially prevented this sharp decrease in eNOS rnRNA levels in Ml 
animals (Figure 3B). Similar positive metformin effects were found for procollagen 
and collagen l expression, which were significantly increased in the Ml group as 
compared to sham, and with a trend to a limited increase in the metformin-treated 
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Figure 4. Effects of mctfonnin on protein expression. Protein levels of phosphorylation of AMPKaThrI 72, 
phosphorylation of eEF2 Thr56, phosphorylation of p70S6K Thr389 and GLUT4, measured in the border 
zone of the MI tissue is shown for all groups. Panel A: Metformin sign ificantly increased the 
phosphorylation of AMPKaThrI 72 after 1 2  weeks both in sham and MI operated groups. Panel B:  
Mctfonnin sign ificantly increased the phosphorylation of cEF2 Thr56 12 weeks after MI;  Panel C: 
Metfonnin did not affect the phosphorylation of p70S6K Thr389 among all groups; Panel D: GLUT4 
expression is decreased in the M I  group after I 2 weeks M I ;  Mctformin restored this. N:7-9 for all groups. 
*P<0.05 vs. sham group; #P<0.05 vs. M I  group. 
Cardiac protein expression 
To study the molecular effects of metformin treatment, the phosphorylation of AMPK, 
eEf2, p70S6K were measured in the heart, as well as GLUT-4 protein levels (Figure 4). 
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Furthermore, the cleaved (active) form of the apoptotic protease Caspase-3, AMPK 
isoforms al, a2 and phosphorylated Akt were measured (Figure 5). Metformin 
treatment led to a significant increased phosphorylation of AMPK in both treatment 
groups (Figure 4A), as well as an increased phosphorylation of eEF2 (Figure 4B), 
while there was a non-significant difference found in the AMPK downstream protein 
p70S6K phosphorylation (Figure 4C). GLUT4 expression is decreased in the MI group 
after 12 weeks Ml; Metformin restored this (Figure 4D). There were no differences of 
AMPK al and a2 expressions among all the groups (Figure SA and 5B). No 
significant differences in Akt phosphorylation were observed among all groups (Figure 
SC). Total Caspase-3 levels were equal in all groups, while cleaved activated Caspase-3 
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Figure 5. Effects ofmetformin on protein expression. Protein levels of total AMPKa, AMPKal,  AMPKa2, 
phosphorylation of Akt Ser473 and cleaved caspase-3 measured in the border zone of the MI t issue is 
shown for all groups. Panel A, B and C: AMPKa, AMPKal,  AMPKa2 were equally expressed among all 
groups corrected for GAPDH; Panel D: No significant differences were found on Akt Ser473 
phosphorylation among all groups; Panel E: Cleaved caspase-3 expression was increased in the MI group 
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Figure 6. Cardiomyocyte size, infarct size and left ventricular interstitial fibrosis were measured by 
histology. Panel A: MI was associated with an increase of cardiomyocyte size, and this increase was not 
modified by metformin treatment. Panel B:  Infarct size was measured by sirius red/fast green staining; 
infarct sizes are presented in Table 2. Panel C: MI induced an increase of interstitial fibrosis of the left 
ventricular free wall remote from the infracted area, which was partially attenuated by 12 weeks metformin 
treatment. *P<0.05 vs. sham group. 
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Left ventricular hypertrophy and interstitial fibrosis 
The cross-sectional area of cardiomyocytes was increased in both Ml groups compared 
to sham groups, and metformin treatment had no effect on the cardiomyocyte 
hypertrophy in the post-Ml heart failure model (Figure 6A). This contrasts with the LV 
weights corrected for body weights ratios reported in table 2, which probably is 
explained by differences in body weights rather than LV weight.Post-Ml heart failure is 
accompanied by increased fibrosis, which was non-significantly reduced by metformin 
(Figure 6C). 
Discussion 
Our study demonstrates that long-term metformin administration is associated with 
preserved cardiac function in a rat model of post-Ml cardiac remodeling. The key 
findings are that long-term (12 weeks) metformin treatment after Ml significantly 
attenuated cardiac remodeling post Ml, evidenced by I) reduced MI size; 2) improved 
LV geometry (measured by echocardiography); 3) less increase in molecular correlates 
of LV remodeling (amongst others, less ANP and collagen production); 4) measures of 
improved glucose and cellular energy metabolism. 
Until recently, metformin was contraindicated in HF, mainly because of concerns 
about lactic acidosis. However, epidemiological data suggest that metformin is safe and 
may even be the first choice anti-diabetic drug in HF patients with diabetes. In a 
case-control study in patients with diabetes and HF (N=l.633), metformin was 
associated with a reduced all cause-mortality (adjusted Odds Ratio (OR) 0.72; P=0.003) 
27• In diabetic patients with newly established HF (N=l .305), metformin monotherapy 
was associated with a reduced I -year mortality when compared with sulfonylurea 
treatment 28• In HF patients admitted to the hospital (N= I 6.417), metformin use was 
associated with a lower I-year mortality when compared to treatment with insulin or 
sulfonylurea (24.7% vs. 36.0%, P<0.0001 )  29• All-cause re-admission and HF 
hospitalization were also less common in diabetic patients treated with metformin than 
in those not treated with an insulin-sensitizing drug. Although results from prospective 
randomized placebo controlled clinical trials are lacking, these data strongly suggest 
that metformin use is associated with a better outcome in clinical HF in diabetic 
patients. 
It has been shown that metformin exerts cardioprotective effects in various 
experimental set-ups, although mostly acute cardiac damage models. First, Solskov et 
al reported that metformin exerted a protective effect on the rat heart subjected to 
cardiac ischemia/reperfusion injury in an in vitro Langendorff setup 1 2• This study 




administered before a coronary occlusion was inflicted. Another acute study confirmed 
the cardioprotective effect of metformin in mice subjected to cardiac 
ischemia/reperfusion model in vivo, also when administered during the reperfusion 
stage 30• This indicated that also in vivo, metformin exerts protective effects after Ml, 
which was confirmed in another study with a longer follow-up, showing improved left 
ventricular function and survival in mice subjected to ischemia reperfusion injury 8. 
Moreover, metformin was shown to attenuate cardiac fibrosis induced by pressure 
overload in mice model and inhibited collagen synthesis 1 3. Interestingly, in dogs in a 
model of rapid pacing metformin could also prevent progression of HF 1 1 • The precise 
actions of metformin on the heart are still not fully elucidated, but a central role of 
activation of AMPK, which is a regulator of cellular energy formation, has been 
proposed K, 1 1 , t3 ,  30_ 
Our study is unique in that it used a model of chronic (instead of temporary) 
ligation of a coronary artery, which leads to large myocardial infarction and cardiac 
remodeling that resembles the human sequel of events. We herein show that chronic 
metformin treatment is associated with a decreased extent of myocardial damage, 
possibly due to both necrosis and apoptosis resulting in reduced Ml size, which is 
associated with less remodeling over time. Metformin has been shown to inhibit 
apoptosis, as reported in a dog model of heart failure 1 1 • We found that cleaved 
caspase-3 levels were increased post-Ml, as reported before 3 1 ; however the use of 
metformin only non-significantly reduced caspase-3 levels. Increased levels of the 
anti-apoptotic protein Akt arc associated with suppression of AMPK phosphorylation, 
which can be restored by metformin 32• On the other hand, Sasaki et al. 1 1  showed that 
metformin treatment causes decreased Akt phosphorylation in failing hearts. In our 
study, the use of mctformin was not associated with meaningful differences in 
phosporylatcd levels of Akt. Therefore we conclude that the beneficial effects of 
mctformin cannot, or only marginally, be explained by differences in apoptosis. We 
furthermore confirm the inhibitory effect of metformin on fibrosis, evidenced in 
multiple experimental models, indicating that this is a general metformin associated 
cardiac phenomenon and not only linked to pressure overload model and pacing mode 
1 1 •  1 3• In our study, we observed a decreased expression of collagens and reduced 
fibrosis. 
In support of another study 8, the cardioprotective effects appeared to be 
independent of antihyperglycemic effects of metformin. In fact, fasting glucose levels 
and OGTTs were similar in all groups, despite lower insulin levels in the metformin 
treated animals. This suggests an insulin sensitizing effect of metformin, resulting in 
insulin level reductions, lower myocardial glycogen content, enhanced GLUT4 
expression, while maintaining normal plasma glucose levels. These observations 
suggest an improved myocardial glucose uptake, but we did not measure this. Except 
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for insulin, plasma levels of other metabolic hormones did not change, indicating that 
metformin did not generate major systemic changes. Nevertheless, weight gain in 
metformin treated animals was reduced and this could not be simply related to changed 
food uptake. Although, we cannot exclude that nutrient uptake in the intestine has 
changed, our observation that metformin activates AMPK might point more into the 
direction of increased cellular metabolism. As described, AMPK is an enzyme that is 
activated in response to changes in cellular energy metabolism, for instance in muscle 
contraction, ischemia or by pharmacological agents like metformin 33. In our study, 
metformin treatment led to an increased phosphorylation of AMPK, resulting in an 
increased phosphorylation of one of its downstream targets, eukaryotic elongation 
factor-2 (eEF2). Moreover, activated AMPK has a fundamental role in glycogen 
synthesis and glucolysis 34, which is supported by our study showing that long-term 
metformin treatment causes a decreased glycogen content in the myocardium, an 
observation that is common to most antidiabetic drugs 35. All these effects suggest that 
metformin may restore the cellular energy flux by inhibition of processes that switch 
off the ATP-consuming pathways to protect the stressed heart 36• 
We observed a strong insulin lowering effect of chronic metformin treatment. It 
has become apparent that a strong association exists between hyperinsulinemia and 
incident heart failure. A recent paper provided proof that cardiac insulin signaling itself 
also exacerbates cardiac remodeling 37. Therefore, part of the beneficial effects that we 
report herein may be due to low insulin levels and signaling. 
AMPK is activated during caloric restriction and stimulates cellular metabolic 
pathways in order to maintain energy supply. Interestingly, caloric restriction confers 
cardioprotective effects and metformin-treated animals and long-term dietary 
restriction animals have similar gene expression patterns 38. Together, this might 
suggest that the activation of certain AMPK downstream effectors in the heart, rather 
than changes in cellular metabolism itself, confers cardioprotective effects. 
Limitations of the study 
Sample size and thus power is limited. We started administration of metformin two 
days before MI, so we cannot separate early and late protective effects in this study. 
The dose of metformin used in this study was comparable to other studies in rodents 
and humans (200mg-350mg/kg/day) 15• 39, we established this dose did not cause 
side-effects like hypoglycemia and renal dysfunction ( data not shown). Since 
metformin affects various targets, including AMPK and many downstream targets, the 






In summary, our study demonstrated that metformin exerts a protective effect on 
cardiac remodeling in non-diabetic rats with post-Ml heart failure. We postulate that 
AMPK and low insulin levels are important mediators in the protective effects. These 
findings underscore the potential beneficial effects of metformin in HF, and provide 
further evidence that metformin should be prospectively tested for its safety and 
efficacy in HF, e.g. in a post-Ml trial. We recently launched such a trial (Metformin to 
Reduce Heart Failure After Myocardial Infarction; NCT0 1217307). 
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Chapter 4 
Abstract 
Background: Progressive remodeling after myocardial infarction (MI) is a leading 
cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)- 1 was shown 
to have cardioprotective effects, but treatment with GLP- 1 is limited by its short half­
life. It is rapidly degraded by the enzyme dipeptidyl peptidase-4 (OPP-4), an enzyme 
which inhibits GLP- 1 activity. We hypothesized that the DPP-4 inhibitor vi ldagliptin 
will increase levels of GLP-1 and may exert protective effects on cardiac function after 
Ml. 
Methods: Sprague-Dawley rats were either subjected to coronary ligation to induce Ml  
and left ventricular (LV) remodeling, or sham operation. Parts of the rats with an M l  
were pre-treated for 2 days with the DPP-4 inhibitor vildagliptin (MI-Vildagliptin 
immediate, MI-VI, 15mg/kg/day). The remainder of the rats was, three weeks after 
coronary artery ligation, subjected to treatment with DPP-4 inhibitor vildagliptin (Ml­
Vildagliptin Late, MI-VL) or control (Ml) At 12 weeks, echocardiography and invasive 
hemodynamics were measured and molecular analysis and immunohistochemistry 
were performed. 
Results: Vildagliptin inhibited the DPP-4 enzymatic activity by more than 50% and 
increased active GLP- 1 levels by about 3-fold in plasma in both treated groups (p<0.05 
vs. non-treated groups). Cardiac function (ejection fraction) was decreased in all 3 MI 
groups compared with Sham group (p<0.05); treatment with vildagliptin, either early or 
late, did not reverse cardiac remodeling. ANP (atrial natriuretic peptide) and BNP 
(brain natriuretic peptide) mRNA levels were significantly increased in all 3 MI groups, 
but no significant reductions were observed in both vildagliptin groups. Vildagliptin 
also did not change cardiomyocyte size or capillary density after Ml. No effects were 
detected on glucose level and body weight gain in the post-MI remodeling model. 
Conclusion: Vildagliptin increases the active GLP-1 level via inhibition of DPP-4, but 
it has no substantial protective effects on cardiac function in this well established long­
term post-MI cardiac remodeling model. 
Key words: vildagliptin, myocardial infarction, cardiac remodeling, heart failure, 
diabetes 
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Introduction 
Glucagon-like peptide- l (GLP-1; 7-36 amide), which belongs to the proglucagon 
family of incretin peptides, is secreted by enterendocrine L cells of the intestinal 
mucosa and released in response to food intake 1 • GLP-l analogues have been used for 
the clinical treatment of type 2 diabetes because of its multiple actions on pancreatic 
function 24. Besides its effects on glucose metabolism, GLP-l has been proven to exert 
cardiovascular effects in clinical and experimental studies, in the presence or absence 
of diabetes 5• 
GLP- l receptors (GLP- l R) are expressed in rodent and human heart and 
vasculature 6-8. GLP- lR deficient mice exhibit increased left ventricular (L V) thickness, 
impaired LV contractility and LV diastolic function compared with control mice 9• 
However, whether the beneficial effects of GLP-l on the heart are conferred through 
direct GLP-lR signaling or indirect, through the GLP-I R-dependent improvement in 
glucose metabolism is not well established. Administration of GLP-1 improves 
myocardial function and cardiac output in experimental models of cardiac injury or 
heart failure. GLP-1 increased cardiac output, and reduced L V end diastolic pressure, 
in association with improved myocardial insulin sensitivity and myocardial glucose 
uptake in dogs with rapid pacing-induced congestive heart failure 10. Consistent with 
the cytoprotective action of GLP-1 in the endocrine pancreas, GLP-1 reduced infarct 
size in the isolated perfused rat heart and in animal models of myocardial ischernia 1 1 - 1 3 _ 
A 72 hours infusion of GLP- 1 in patients with acute myocardial infarction (Ml) and an 
L V ejection fraction (L VEF) less than 40% resulted in significantly improved L VEF 
and improved regional and global wall motion scores, in association with a trend 
towards earlier hospital discharge 1 4• In a pilot study of both diabetic and non-diabetic 
subjects with heart failure, an improved L V function was observed following a 5 week 
continuous infusion ofGLP- 1(7-36) 5• 
However, active GLP-1 in the circulation is rapidly (within two minutes) 
degraded by dipeptidyl peptidase-4 (DPP-4) 15• An alternative approach for enhancing 
GLP-1 action involves the use of DPP-4 inhibitors. The DPP-4 inhibitor sitagliptin 1 6  
and saxagliptin 1 7  have been approved for type 2 diabetic patients. Vildagliptin is 
approved and used in Europe 1 8• 
The studies on cardiovascular effects of GLP-1, discussed above, have 
consequently assessed only short-term improvements in cardiac performance, like in 
post-ischemic or cardiomyopathy states. There are no reports on long-term effects of 
DPP-4 inhibition in a post-Ml cardiac remodeling model. Furthermore, the actions of 
DPP-4 inhibitors on cardiac remodeling after Ml are incompletely understood. We 




infarcted hearts by inhibiting the degradation of active GLP- 1 and other cardiovascular 
peptides. The purpose of our study was therefore to determine whether vildagliptin has 
beneficial effects on long-term post-MI remodeling in rats and to explore the 
mechanisms underpinning these effects. 
Methods and Materials 
Animals 
Male Sprague-Dawley rats (Harlan, Zeist, The Netherlands) weighing 250-260g were 
housed in groups of 4-5 on a 12-hour light-dark cycle with standard rat chow and water 
available ad libitum. The animals were subjected to sham-surgery or left coronary 
artery ligation. All experiments were carried out after approval of the Animal Ethical 
Committee of the University of Groningen for the use of experimental animals and 
conform to the Guide for Care and Use of Laboratory Animals. 
Drugs 
The DPP-4 inhibitor vildagliptin was kindly supplied by Novartis, The Netherlands. 
Vildagliptin was dissolved in the drinking water and administered in a final 
concentration of 15mg/kg/day, which is chosen according to the previous studies 1 9• 20 
Experimental protocol 
Rats were randomly subjected to induction of MI or sham surgery. Briefly, animals 
were intubated and mechanically ventilated with 2.5% isoflurane in room air emiched 
with 1 .0L/min oxygen. After left-sided thoracotomy, MI was induced by ligating the 
proximal portion of the left coronary artery. In sham-operated rats, the same surgery 
was performed without ligating the suture. Parts of the rats with an MI were pre-treated 
for 2 days with vildagliptin (MI-Vildagliptin immediate, Ml-VI). The remainder of the 
rats was, three weeks after coronary artery ligation, subjected to treatment with DPP-4 
inhibitor vildagliptin (Ml-Vildagliptin Late, Ml-VL) or control (Ml). At week 12, 
cardiac function was determined by echocardiography. After 1 2  weeks, rats were 
anaesthetized and hcmodynamic function was measured invasivcly; thereafter blood 
was drawn ( either anticoagulated with EDT A, or left to clot for serum) and the hearts 
were rapidly excised. Myocardial tissue was sectioned transversally and processed for 
immunohistochemistry or snap-frozen for molecular analysis. 
Echocardiographic measurements 
Cardiac function was assessed by echocardiography by a Vivid 7 (GE Healthcare) 
equipped with a IO-MHz phase array linear transducer. The echocardiographic 
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measurements were performed under general anaesthesia with 2.5% isoflurane, by a 
researcher blinded for the treatment allocation. Both 2-dimensional (2D) images in 
parasternal long-axis and short-axis view and 2-D guided M-mode tracings were 
obtained. Short-axis views were recorded at the level of mid-papillary muscles. L V 
internal dimensions in diastole and systole {LVIDd and LVIDs) were measured using 
M-mode and calculated from three cardiac cycles. LV fractional shortening (FS %) was 
calculated as follows: FS = {L VIDd-L VIDs )/L VIDdx 1 00%. L V ejection fraction (EF 
%) was calculated using the Teichholz method. 
Hemodynamic measurements 
At sacrifice, rats were anesthetized and a micro-tip pressure transducer (Millar Instr. 
Inc., Houston, TX, USA) was inserted into the right carotid artery. Arterial systolic and 
diastolic blood pressures (SBP, DBP) were recorded in the aortic arch. The catheter 
was advanced into the LV cavity. After a 5-min period of stabilization, heart rate (HR), 
LV systolic pressure {LVSP), LV end-diastolic pressure {LVEDP), and developed L V 
pressure ( dLVP=L VSP-L VEDP) were measured. For indices of contractility and 
relaxation, the maximal rates of increase and decrease in L VP dp/dtmax and dpldtmin 
were determined. 
Procurement of heart tissue and infarct size measurement 
After the rats were euthanized, hearts were rapidly excised and arrested in diastole in 
2M ice-cold KC!. The total heart was weighed (heart weight, HW). The right ventricle 
and atria were removed, and the left ventricle was weighed (left ventricular weight, 
LVW). The basal and apical parts of the LV were snap-frozen in liquid nitrogen. A 
mid-papillary slice of the L V was fixed in 4% paraformaldehyde overnight and 
paraffin-embedded. Paraffin blocks were sectioned, and slides were dehydrated. The 5 
µm sections were stained with picrosirius red/fast green 2 1 • The infarct size was 
calculated as percentage of the scar length to the total L V circumference. The images 
were obtained with a Leica microscope and analyzed using appropriate software 
(Image-pro plus, version 4.5.0.29). 
Active GLP-1 assay and DPP-4 activity 
EDTA plasma was used to measure active GLP- 1 and DPP-4 activity, using a 
commercial Enzyme Linked lmrnunosorbent Assay, according to the guidelines 
provided by the manufacturer (Quantikine, R&D system, London, UK). 
Analytical procedures 
Glucose levels were measured with a blood glucose monitor (Accu-Check®, Roche, 




commercially available kits (Roche Diagnostics, Mannheim, Germany and DiaSys 
Diagnostic Systerms, Holzheim, Germany). 
Capillary density 
To visualize the capillaries in the myocardium, endothelial cells were stained with 
Lcction GSI (Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands), as previously 
described 22• Briefly, 5-µm sections were deparaffinised and rehydrated and 
endogenous peroxidase was inhibited by methanol/H202 (0.3%) for 15 minutes. 
Sections were incubated overnight with biotinylated Lectin GSI (1 :100) at room 
temperature. Then, in a second step, the signal was intensified with an ABC-complex 
containing peroxidase labeled biotins ( I :  100) (Lab vision, CA, USA). Finally, the 
sections were incubated with a Ni-Co amplified DAB solution to which a stable 
peroxide substrate buffer was added (Pierce, CA, USA). Endothelial cells of capillaries 
and larger vessels were visualized in the myocardium as a brown precipitate. A 
background staining was not used in order to avoid interference with the Lectin 
staining. Capillary density in the viable L V wall was calculated as the number of 
capillaries per tissue area. 
Left ventricular hypertrophy 
First, left ventricular hypertrophy was expressed as the ratio of left ventricular weight 
to body weight. Microscopically, left ventricles were cut into 5 µm transversal slices 
from apex to base. Afterwards, sections were stained with a Gomori' s  silver staining in 
order to visualize the membrane of the cardiomyocytes, as described previously 2 1 • 
Cardiomyocyte size was measured transversally cut in the border zone of the infarcted 
area using image analysis (Zeiss KS400, Germany). 
Real-time PCR 
We used myocardial tissue (of border zone of the infarction) to extract total RNA with 
TRlzol reagent (lnvitrogen Corp., Carlsbad, CA, USA). The nano-drop device was 
used to quantify the RNA concentration. First strand cDNA was synthesized by reverse 
transcription reaction by using random primer mix, and used as a template to amplify 
genes of interest; for this specific primers against ANP (atrial natriuretic peptide), 
BNP (brain natriurctic peptide), collagen I, MMP-9 (matrix metalloproteinase-9) were 
designed. All gene expression values were normalized to 36B4 mRNA levels. 
Data analysis 
All data are presented as means ± standard errors of the mean (sem). Data of infarcted 
rats were only included if the infarction comprised the major part of the LV free wall, 
since small infarctions ( <20%) are found to be hemodynamic fully compensated (two 
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animals were excluded from the MI group, and three animals were excluded from each 
vildagliptin-treated groups MI-VI and MI-VL). Statistical analysis among groups was 
performed by one-way analysis of variance (ANOVA) followed by Tukey post-hoc test. 
Within-group comparisons between week 3 and week 12  were analyzed by Paired­
Sample T-Test. Differences were considered statistically significant if p<0.05. 
Results 
Active GLP-1, DPP-4 activity and glucose levels 
We measured the DPP-4 activity and active GLP-1 levels in plasma after 1 2  weeks of 
vildagliptin treatment to confirm that continuous administration of vildagliptin 
(supplied at 20mg/kg in the drinking water) was indeed associated with suppression of 
plasma DPP-4 activity, and increase in the active GLP-1 levels. Plasma DPP-4 activity 
was significantly reduced by almost 70% in both treatment groups compared to non­
treated groups. This was associated with a significant increase of the active GLP-1 
level in both vildagliptin groups (Figure I). 
During the 12 weeks of follow up, we measured glucose levels at baseline, week 
6 and week 12. No significant changes in glucose levels were observed, suggesting that 
vildagliptin has no effect on normal glucose levels. The similar findings were observed 
in plasma cholesterol and triglycerides that no significant differences were found 
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Figure 1 .  Effects of Vildagliptin on DPP-4 activity and active GLP-1 levels.A: Vildagliptin reduces DPP-4 
activity after 1 2  weeks treatment. B: Vildagliptin increases active GLP-1 levels in plasma after 1 2  weeks 





Body Weight, LV weight, and infarct Size 
Body weight (BW), L V weight (L VW) to body weight ratios (L VW /BW) and infarct 
sizes are shown in Table I A. Ligation of the left coronary artery resulted in an infarct 
size of 47±2 % in control-treated MI group (Figure 2B). Although there was no 
significant reduction in the infarct size, vildagliptin treatment (both immediate and late) 
was associated with a trend towards smaller infarct size over the 3-month period of 
treatment compared with the MI control group (Figure 2B) .Thcrc was no difference in 
body weight between groups both at baseline and at 12  weeks after Ml surgery. The 
LVW/BW ratios in all Ml groups were significantly increased compared to LVW/BW 
of the sham-operated group, however, LV hypertrophy was not significantly reduced 
by vildagliptin treatment (both groups) compared to MI control (Table I A). 
Table 1 Characteristics of the experimental groups at sacrifice (12 weeks). 
Sham MI MI-VI MI-VL 
N=S N=lO N=9 N=9 
A BW (g) 321±9 313±5 321±2 306±4 
(baseline) 
BW (g) 446±15 449±1 1  436±5 450±7 
(12 week) 
LVW (g) 0.93±0.03 1 .05±0.03* 0.97±0.02 1.08±0.03* 
(12 week) 
LVW/BW 2.00±0.05 2.34±0.09** 2.22±0.05 2.39±0.05** 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ·  
8 Glucose(mmol/L) 9.00±0.61 7.97±0.47 7.81±0.3 1  9.52±0.42 
(3 week) 
Glucose(mmol/L) 7.15±0.2 1 7.25±0.28 7.06±0. 1 4  7.67±0.17 
(6week) 
Glucose (mmol/L) 8.01±0.34 7.3 1±0.20 7.99±0.3 1  7.64±0.22 
(12week) 
Cholesterol 1 .49±0.09 1.48±0.04 1.45±0.08 1 .39±0.07 
(mmol/L) 
Triglycerides 0.95±0. 1 9  1.12±0.13 0.84±0. 1 1  0.86±0. 1 2  
(mmol/L) 
Data arc presented as mean ± SEM; N indicates number of animals; BW, body weight; LVW, left ventricle 
















Ml Ml-VI Ml-Vl 
Figure 2. A: Sirius red and fast green staining of rat myocardium shows the infracted area with the red 
color in all groups. B: Graphic representation of infarct size expressed as percentage of the scar length to 
the total L V circumference. C: Temporal changes in ejection fraction in the presence or absence of 
vildagliptin treatment in all groups. Data are presented as mean±SE. N=8-I O for all groups. 
L V hemodynamic and echocardiographic parameters 
All MI rats showed evidence of heart failure, including development of L V dilatation 
and L V systolic dysfunction at both 3 weeks and 12 weeks after MI. Three weeks after 
MI, there was a significant decrease in all MI groups in FS and L VEF compared with 
the sham-operated group, as well as an enlarged chamber size (L VID) and a thinner 
wall thickness (IVS) in both systole and diastole (Table 2). During the following 9 
weeks, a continued L V chamber enlargement and interventricular septum wall thinning 
was observed in all MI groups compared with the sham group. Although most 
echocardiographic parameters were not significantly different between the MI control 
group and the vildagliptin-treated groups, comparisons between 3 weeks and 12 weeks 
echocardiographic studies demonstrated that the progressive L V dilatation and wall 
thinning in the MI control group was attenuated in the vildagliptin-treated groups 
(Table 2). The L VEF in MI control group decreased from 49±3% at 3 weeks to 36±5 % 
at 12 weeks, while in the early vildagliptin it decreased from 48±4% to 45±5%, and in 
the late vildagliptin group from 49±3% to 48±4% (Table 2). The differences in L VEF 
at 12 weeks between the MI-control and the MI-vildagliptin groups were not 
significant. Thus, a significant worsening of L VEF was observed in the MI control 
group as compared to both vildagliptin groups. 
Hemodynamic abnormalities were characteristic for rats with HF in the MI 
control group. Specifically, MI control rats showed significantly depressed dp/dtmax 
8 1  
II 
� I  Table 2 Echocardiographic parameters of the experimental groups at week 3 and week 12. 
Week 3 Week 12 
Sham MI Ml+VI MI+VL Sham MI Ml+VI Ml+VL 
N=8 N=lO N=9 N=9 N=8 N=lO N=9 N=9 
HR (bpm) 377±1 1 379±9 383±1 1 407± 1 1  370±12 387±6 377±10 391±6 
IVSd(mm) 1 .5±0.1 0.9:t:0.1•• 1 .0±0.01 *  1 .0±0.1 *  1 .6±0.l  0.8±0.1 ** 1 .0±0.1 *  0.8:t:0. 1•• 
LVIDd(mm) 7.7±0.1 8.3±0.3 8.4±0.2 8.1±0.3 8.0±0.4 l 0. 1±0.3** § 9.7±0.4** § 9.7±0.2 •• § 
LVPWd(mm) 1 .8±0.1 1 .8±0.1 1 .9±0. 1 1 .8±0.1 2.1±0.2 2.3±0.2 2.0±0.12 2.0±0.1 
IVSs(mm) 2.9±0.1 1 .3±0.2* 2.0±0.6 1 .3±0.2* 2.9±0.2 1 .0±0.2•• 1 .2±0.2•• 1.2±0.2** 
LVIDs(mm) 4.2±0. 1 6.5±0.3** 6.0±0.4** 6.3±0.3** 4.6±0.4 8.6±0.5** § 7.7±0.4** 7.6±0.2** § 
LVPWs(mm) 2.9±0.1 2.7±0.1 2.6±0.2 2.5±0.1 2.9±0.2 2.7±0.3 2.6±0. 1 2.6±0.2 
LVEF (%) 81 .5±1 . 12  49.4±2.7** 47.5±4.4** 49.4±2.9** 78.1±3.2 36. 1±5.1  •• § 45.4±4.5** 48.0±3.7** 
%F'S 45.5±1.7 22. 1±1 .5•• 2 1 .4±2.4** 22. 1±1 .5** 43.0 ±3.l  1 5  .9±2. 7* *§ 20.5±2.4** 2 1 .9±2.4** 
Data are presented as mean :I: SEM; N indicates number of animals; bpm, beats per minute. **P<0.0 l and *P<0.05 indicate significant differences 
compared to sham-operated rats in week 3 and week 12 respectively; § P <0.05 indicates significant difference between parameters at week 12 
and week 3 using Paired-Sample T-Test. IVSd and IVSs, the thickness of the interventricular septum in diastole and systole; LVIDd and LVIDs, 
diastolic and systolic left ventricle dimensions; L VPWd and L VPWs, the thickness ofleft ventricle posterior wall in diastole and systole. 
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DPP-4 inhibiton in post-MI heart failure 
Capillary density and cardiomyocyte size 
Capillary density was significantly reduced in all post-MI groups compared to sham­
operated rats (p<0.01) (Figure 3). Cardiomyocyte size significantly increased in all 
post-Ml groups compared to sham (p<0.01). Vildagliptin treatment both in early and 
late phase led to a trend towards diminished cardiomyocyte hypertrophy but no 
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Figure 3. Effects of vildagliptin on capillary density in cardiomyocyte cross-sectional area. A: Graphic 
representation of capillary density expresses as the number of capillaries/mm2 field. B: Typical examples of 
capillary density in the experimental groups at x40 magnification. Data are presented as mean±SE. N=S-10 










Figure 4. Cardiomyocyte size was measured by gomori staining in cross-sectional areas. A: Graphic 
representation of cardiomyocyte size in all experimental groups. B: Typical examples of cardiomyocyte size 
in the experimental groups at x40 magnification. Data are presented as mean±SE. N=S-10 for all groups. 




Table 3 Hemodynamic parameters of the experimental groups at sacrifice (12 weeks). 
Sham MI MI-VI MI-VL 
N=8 N=lO N=9 N=9 
Heart rate (bpm) 346±16 378±7 350±9 361±12 
LVESP (mmHg) 117±4 1 09±3 1 08±3 109±4 
LVEDP (mmHg) 6.2±0.8 9.6±1.6* 9.8±1 .3* 7.4±0.5 
SBP (mmHg) 1 15±3 1 11±2 1 1 0±3 113±3 
DBP (mmHg) 87±2 86±2 85±2 84±2 
dPdtmax (mmHg/s) 8744±435 7245±436 6908±396 7952±484 
dPdtmin (mmHg/s) -9363±268 -6419±466* -6592±613* -7077±380* 
Data are presented as mean ± SEM; N indicates number of animals; LVESP, left ventricular end-systolic 
pressure; LVEDP, left ventricular end-diastolic pressure; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; dP/dtmax and dP/dtmin, the maximal rate of increase and decrease of left ventricular 
pressure, respectively.*P<0.05 vs. Sham. 
Cardiac gene expression 
ANP and BNP mRNA levels were significantly increased both in the MI control group 
as well in as late vildagliptin treatment group compared to sham group (p<0.05). 
Vildagliptin treatment both in early and late phase had no significant effects herein 
(Figure SA and 5B). Similar results were found for collagen I expression, which was 
significantly increased in the MI group compared to sham, while no difference was 
observed in collagen I expression between vildagliptin-treated groups and the control 
MI group (Figure SC). MMP-9 mRNA levels were similar in all groups (Figure 5D). 
Discussion 
In the present study, we demonstrate that long-term treatment of the DPP-4 inhibitor 
vildagliptin in rats with L V remodeling due to MI increases endogenous active plasma 
GLP-1 levels, via inhibition of DPP-4 activity. However, this did not result in a 
decreased infarct size nor did it attenuate cardiac remodeling associated with post-MI. 
No differences in glucose levels and body weight were found in these non-diabetic rats 
when treated with vildagliptin. 
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Figure 5. Quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR) was conducted 
and expression was measured of myocardial atrial natriuretic peptide (ANP; A), brain natriuretic peptide 
(BNP; B), collagen I (C), and MMP-9 (D), respectively (mRNA corrected for 3684 mRNA level). The 
relative corrected values are shown for each group. Data are presented as mean±SE. N=8-I O for all 
groups. *P<0.05 vs. sham group. 
To our knowledge, this is the first study to assess the effects of immediate and 
late vildagliptin treatment in a non-diabetic rat model. We furthermore aimed to dissect 
immediate versus late effects of DPP-4 inhibition. We herein show that neither early 
nor late vildagliptin treatments exert beneficial effects in MI-induced deterioration in 
cardiac remodeling. Notably, Ml size was (non-significantly) smaller in the vildagliptin 
treated rats. However, this effect was observed both in rats immediately treated with 
vildagliptin as well as in rats in which treatment with vildagliptin started after 3 weeks, 
so when the infarction scar is fully organized. From this, we postulate that vildagliptin 
is unlikely to reduce infarct size. The associated differences in L VEF may be ascribed 
to the differences in infarct size. Other measures of L V remodeling were also 




not reverse the Ml-induced decrease in capillary density, measured at the border zone 
of the infarcted myocardium. Similarly, both early and late vildagliptin treatment did 
not counteract Ml-induced cardiomyocyte hypertrophy. Furthermore, both early and 
late vildagliptin treatment had no effects on the Ml-induced increases in cardiac 
expression of ANP, BNP. ANP and BNP cardiac gene expression closely associates 
with the severity of L V dysfunction 23, so this finding supports the notion that cardiac 
remodeling is not affected by vildagliptin. Furthermore, the expression of matricellular 
proteins collagen I and MMP-9 were also not affected by vildagliptin treatment. 
A number of acute studies have been previously performed with DPP-4 
inhibitors, GLP-1 or GLP-1 analogues, addressing their role in cardioprotection. A 
study with the DPP-4 inhibitor PFK275-055, a vildagliptin-analogue, showed a 
reduced infarct size with activation of the cardioprotective RISK (reperfusion-induccd 
salvage kinase) pathway in pre-diabetic rats 24, whereas a study with the DPP-4 
inhibitor sitagliptin showed that infarct size or short-term cardiac function were not 
affected by the treatment 25• The latter study is in line with our study. 
Another mean of increasing GLP- 1 is direct GLP- I infusion. Acute GLP- 1 
infusion studies both in patients and rodents did show beneficial effects. In a clinical 
study, 3-day infusion of GLP-1 improved LV function in patients after acute MI 14• 
Moreover, ischernia/reperfusion experiments in rats showed that GLP-1 administration 
prior to the ischemia leads to smaller infarct size in the isolated heart 1 1 • 1 2• 26• Another 
ischemia-reperfusion study showed that only the GLP- 1 analogue exendin-4, but not 
GLP-1(9-36) amide exerts infarct-limiting action, while both of them improved LV 
performance 27• Apparently, GLP-1 infusion provides a stronger effect than DPP-4 
inhibition, probably due to a stronger elevation of GLP-1 levels. The published results 
from DPP-4 inhibition studies arc variable and this might be explained by different 
levels of inhibition (different inhibitors used, different dosages), and variable levels of 
GLP-1. 
So, although a number of acute studies have been performed, only few chronic 
studies have addressed the effects of GLP- 1 on cardiac function in non-diabetic models. 
A chronic (3 month) infusion study showed that GLP-1 improved LV systolic function 
and prolonged sw-vival in spontaneously hypertensive rats by increasing myocardial 
glucose uptake and reducing myocyte apoptosis 28• Treatment with either GLP-1 or 
excnatidc analogue AC3 l 74 also demonstrated promising cardioprotective effects, 
including improved L VEF, LV end-diastolic pressure, and cardiac dimensions in a rat 
MI model (comparable to the present model) 29• Our results arc not in concert with the 
observations that cardioprotection is achieved by GLP-1 treatment. The reasons for the 
discrepancies between the present study and earlier work may be attributable to the 
dosing regimen, the different analogue utilized, the levels of GLP-1 achieved, and the 
timing of the treatment and the species studied 30• 
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Furthermore, a number of other issues should be considered when discussing the 
lack of vildagliptin-induced cardioprotection as observed in our study. First, we used a 
model of non-diabetic rats, with normal glucose levels. Vildagliptin is an antidiabetic 
agent which exerts its beneficial effects in the cardiovascular system through 
glycometabolic control. Thus it may be possible that vildagliptin is more beneficial in 
diabetic models. Second, as a DPP-4 inhibitor, vildagliptin inhibits degradation of 
GLP- 1 and prolongs its half life in vivo; however, its effects are less strong than 
continuous GLP- 1 infusion. The elevations in GLP-1 levels achieved by vildagliptin 
are likely to be lower than achieved by GLP- 1 infusion and thus insufficient to produce 
cardioprotection. Finally, we do not know if other, hitherto unknown mechanisms, may 
underpin the effects of vildagliptin in the heart. To date, limited data are available 
describing the effects of vildagliptin on the cardiovascular system. 
In addition, the biological effects of DPP-4 inhibitors appear different from 
GLP-1 and other GLP- l R  agonists 3 1 • Vildagliptin treatment has no effect on body � 
weight, food intake, energy expenditure and insulin sensitivity 4• 32• 33. Although it has I.I 
been shown that vildagliptin reduced plasma cholesterol and triglycerides in diabetic 
patients 34• 35, no effects of vildagliptin on these parameters were found in our post-MI 
animal study. However, GLP-1 inhibits glucagon secretion and controls body weight 
by decreasing food intake, increase insulin sensitivity and improve glucose uptake, 
which are beneficial cardiovascular factors 36"38. Moreover, the protective effects of 
GLP-1 are also mediated through GLP- lR-independent pathways, partially though 
beneficial effects of its metabolite GLP-1 (9-36) 39. These differences might explain 
why we observed only limited improvements in our study with vildagliptin as 
compared to other studies with GLP-1 and GLP-1 analogues. 
Limitations 
Possibly, the dosage of vildagliptin was not sufficient to observe a cardioprotective 
effect of vildagliptin. We did not include a group treated with GLP- 1 infusion so we 
cannot compare DPP-4 inhibition to GLP-1. Furthermore, although plasma glucose 
was comparable in all groups, we did not assess factors associated with myocardial 
glucose metabolism, so that we cannot rule out if direct metabolic effects explain the 
results. 
Conclusions 
Long-term treatment with the DPP-4 inhibitor vildagliptin, started immediate or late 
after MI, does not preserve cardiac function in a rat post-MI remodeling model of 
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Correction 
The authors would like to correct that the drug substances used in this study was the 
vildagliptin analog PKF275-055. The compound PKF-275-055 is a novel long acting 
oral OPP-IV inhibitor, as an analog of vildagliptin, it has the similar activity as 
vildagliptin. The authors apologize for the error. 
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Abstract 
Background - Long-term metabolic syndrome and diabetes mcllitus arc well­
established risk factors for cardiovascular (CV) disease. A specific CV complication of 
diabetes is diabetic cardiomyopathy: cardiac remodeling in the absence of coronary 
heart disease and hypertension. An emerging treatment for this syndrome is the use of 
glucagon-like peptide- I (GLP- 1 ), a hormone with specific cardioprotcctive effects. 
However, the use of GLP-1 is limited because it is rapidly degraded by the enzyme 
dipeptidyl peptidase-4 (DPP-4). Herc we investigated whether DPP-4 inhibition could 
protect the heart from diabetic cardiomyopathy. 
Methods and results - We studied male Zucker Diabetic Fatty (ZDF) rats ( 1 0  weeks 
of age) and age-matched male Zucker lean (ZL) rats as controls. ZDF rats were 
randomly allocated to the treatment with drinking water containing DPP-4 inhibitor 
(vildagliptin, 3 mg/kg/day) or control water, for 15  weeks. ZDF rats had significantly 
higher plasma glucose levels during compared to ZL, but this was unaffected by DPP-4 
inhibitor treatment. Diastolic cardiac function assessed by echocardiography was 
impaired in ZDF vs. Zucker lean, while systolic function was not affected. This was 
associated with changes in metabolic profile of the heart: significant reduction in 
glucose transporter type 4 (GLUT-4), and an increase of pyruvate dchydrogcnase 
kinase (POK) isozyme 4 and glycogen stores. Furthermore, we observed increased 
myocardial fibrosis in ZDF rats compared to ZL and DPP-4 treatment reduced fibrosis. 
This was associated with reversal of collagen I apposition. Furthermore, these changes 
were associated with an increase of ANP. The functional, morphological and molecular 
changes were partially amenable to DPP-4 inhibition that attenuated cardiac metabolic 
and structural remodeling. 
Conclusion - ZDF rats with severe diabetes mellitus have impaired diastolic function, 
associated with collagen formation and impaired myocardial glucose metabolism, 
suggestive for diabetic cardiomyopathy. DPP-4 inhibition by vildagliptin preserves 





Type 2 diabetes mellitus (T2DM) refers to a metabolic disorder that is characterized by 
high blood glucose due to insulin resistance and relative insulin deficiency 1 • 
Cardiovascular (CV) complications are the leading cause of morbidity and mortality in 
patients with T2DM. The Framingham study showed a higher incidence of heart failure 
(2.4-fold in men and 5-fold in women) in diabetic patients 2, and reported that this 
increased incidence is independent of age, hypertension and coronary artery disease. 
This suggests that diabetes may also directly cause heart failure - known as diabetic 
cardiomyopathy 3• Moreover, diabetic patients with established heart failure have 
worse outcome than non-diabetic patients 4. However, the pathophysiological link 
between diabetes and CV disease and heart failure in particular, is still not well 
understood. 
Many studies have shown that human diabetic cardiomyopathy is characterized 
by diastolic dysfunction with preserved systolic function 5• 6• The early manifestations 
of left ventricular dysfunction in diabetes present as impaired relaxation and abnormal 
filling pattern 7• Diabetic animals have also shown prolongation of relaxation and l!I 
slowing ofrelaxation velocity 8• 1:1 
These observations have been confirmed in animal models of metabolic disease. 
A longer deceleration time and impaired left ventricular early filling were found in 
Otsuka Long-Evans Tokushima fatty (OLETF) rats 9, which are consistent with 
findings in human type 2 diabetic patients w_ Additionally, an increased late mitral 
inflow velocity and increased left ventricular end-diastolic pressure was demonstrated 
in isolated and perfused diabetic rat hearts 1 1 • 
The Zucker Diabetic Fatty (ZDF) rats which have a mutation at the leptin 
receptor gene were used to study more precisely the cardiovascular changes and 
mechanisms in metabolic syndrome 1 2• This model shows the clinical features of the 
metabolic syndrome like hyperglycemia, hyperinsulinemia and hyperlipidemia 1 3• This 
animal model has been used to study the metabolic syndrome and T2DM. 
However, only a limited number of studies have looked into mechanisms 
responsible for the abnormal diastolic function. In a clinical study, diabetic patients 
showed cardiomyocyte hypertrophy and myocardial interstitial fibrosis 14, consistent 
with myocardial alterations in experimental animals 1 5• These findings suggest that 
cardiac hypertrophy and fibrosis are important contributors to the diastolic dysfunction. 
In addition, altered myocardial substrate metabolism reflected in increased Iipolysis, 
impaired myocardial glucose uptake and utilization, and increased FA oxidation also 
contribute to high LV stiffness 16• 
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In our study we targeted the degradation of DPP-4 by administering vildagliptin, 
a DPP-4 inhibitor, to ZDF rats. We first characterized the cardiac phenotype of the 
ZDF rat to gain a better understanding of myocardial maladaptations in diabetic 
cardiomyopathy and second we tested the effect of the DPP4-inhibitor vildagliptin 
herein. 
Materials and Methods 
Animals and experimental protocol. 
All experimental protocols were approved by the Animal Ethical Committee of the 
University of Groningen for the use of experimental animals and conform to the Guide 
for Care and Use of Laboratory Animals. Male Zucker Diabetic Fatty (ZDF) rats (10 
weeks of age) and age-matched male Zucker lean (ZL) littermates were obtained from 
Genetic Models (Indianapolis, IN). Animals were kept in the Animal Care Center at the 
University ofGroningen under controlled conditions (23±1°C; 12:12-h light-dark cycle) 
and received Formula Diet 5008 (protein 26.8%, carbohydrate 56.4%, (91% starch, 9% 
simples carbohydrates), PMI Feeds, Richmond, IN)). ZDF rats were randomly 
allocated to treatment with the DPP-4 inhibitor vildagliptin, dissolved in drinking water, 
or normal drinking water, for a period of I 5 weeks. Body weight and blood samples 
were obtained under anesthesia (2.5% isoflurane in room air enriched with I .0 L/min 
oxygen) at the start of treatment (10 weeks of age) and at the end of treatment (25 
weeks of age). During week 25, cardiac function was determined by echocardiography. 
After I 5 weeks of treatment, rats were anesthetized and hemodynamic function was 
measured invasively; thereafter blood was drawn ( either anti coagulated with EDT A, or 
left to clot for serum) and the hearts were rapidly excised. Myocardial tissue was 
transected transversally and processed for histochemistry or snap frozen for PCR and 
western blot analysis. Aorta was harvested for vascular assessment, as recently 
published 1 7• 
Drug: The DPP4 inhibitor vildagliptin (Galvus®, Novartis Pharma AG, Basel, 
Switzerland) was purchased from the pharmacy in the University Medical Center 
Groningen. Vildagliptin was dissolved in the drinking water and administered in a final 
concentration of 3mg/kg/day. 
Biomolecular assays. 
Arterial blood was collected in EDTA-coated tubes (plasma) or blank tubes (serum) 
and centrifuged at 3000 rpm for 15 min at 4 °C. Thereafter, the plasma/serum was 
divided into different tubes, snap-frozen in liquid nitrogen and stored for future 
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analysis of plasma glucose, lactate, HbAIC, serum insulin, active GLP-1 and TGFP-1. 
Insulin levels were measured at 15 weeks after treatment using an ELISA kit 
(Rat/Mouse insulin 96-well plate assay, Millipore, MA, U.S.A.). 
Insulin resistance assessment by homeostasis model assessment (HOMA-IR) 
HOMA-IR was calculated using the following formula: HOMA index = [fasting insulin 
(mU/mL) xfasting glucose (mmol/L)]/22.5, a value >2.5 is considered to be insulin 
resistance. HOMA-IR has a close correlation with the insulin sensitivity index by the 
standard euglycemic hyperinsulinemic clamp, as shown by Matthews et al 1 8• 
Echocardiography. 
Echocardiographic measurements were performed by one researcher who was blinded 
to the treatment groups (RADB). Rats were anaesthetized with 2.5 % isoflurane in a 
gas mixture of N2O/O2• The M-mode and 2D echocardiography images were obtained 
with a high-resolution system (Vivid 7, GE, Healthcare, Diegem, Belgium), using a IO 
MHz transducer. LV dimensions (LVIDd, LVIDs), measurements of the thickness of 
the interventricular septum (IVSs, IVSd) and posterior wall (LVPWs, LVPWd) were 
recorded. LV fractional shortening (FS %) was calculated as FS = [(LVIDd­
L VIDs )/L VIDd] x 1 00%. Diastolic function was assessed recording inflow pattern of 
the left atrium (E, A, E/A ratio, deceleration time), and by measuring tissue velocity 
imaging (TVI) in the apical 4 chamber recording; septa! and lateral E were recorded 
and the average TVI value are presented in cm/s. 
Hemodynamic measurements. 
Before sacrifice, rats were anesthetized and invasive hemodynamics was measured as 
described 1 9• Briefly, a microtip catheter with pressure transducer (2 Fr, Millar Instr. 
Inc, Houston, TX, USA) was inserted into the right carotid artery and advanced into the 
left ventricular cavity. After five minutes stabilization, the heart rate (HR), left 
ventricular end-systolic pressure (LVESP), end-diastolic pressures (LVEDP) and 
developed left ventricular pressure ( dL VP=LVESP-L VEDP) were recorded. The 
parameters of the maximal rates of increase and decrease in developed L V pressures 
( dP/dtmax and dP/dtmin) were determined. Corrected dP/dtmax and dP/dtmin, the 
maximal rate of increase and decrease of left ventricular pressure divided by systolic 
blood pressure, respectively. 
Tissue procurement; Masson and Sirius red staining for fibrosis. 
After sacrifice, hearts were rapidly excised and arrested in diastole in 2M ice-cold KC!. 
The right ventricle and atria were removed. The basal and apical parts of the L V were 
snap-frozen in liquid nitrogen. A mid-papillary slice of the LV was fixed in 4% 
97 
E 
Vildagliptin in diabetic cardiomyopathy 
paraformaldehyde overnight and paraffin-embedded. The deparaffinized 3 µm sections 
were stained with picrosirius red/fast green, as described previously 20• The collagen 
volume fraction was examined in sections of the left ventricular free wall excluding 
vessels. Tissue sections were stained with Masson's trichrome stain to evaluate the 
extent of perivascular fibrosis, modified from previously described methods 2 1 • The 
area of stained tissue was calculated as a percentage of the total area within a field by 
using image scope software. 
Realtime PCR. 
Total RNA from heart tissue was extracted with TRizol reagent (Invitrogen Corp., 
Carlsbad, CA, USA) and RNA concentrations were measured with a nano-drop device. 
First-strand cDNA was prepared using a random primer mix and thereafter used as a 
template for quantitative real-time reverse-transcriptase PCR (qRT PCR) (25 
ng/reaction). mRNA levels are expressed in relative units based on a standard curve 
obtained by a calibrator cDNA mixture. All measured mRNA expression levels were 
corrected for 36B4 reference gene expression. 
Western blot. 
Myocardial tissue samples (75 mg), taken from the LV, were homogenized in 1 ml 
RIPA buffer (50 mM Tris pH 8.0, 1% nonidet P40, 0.5% deoxycholate, 0.1% SOS, 150 
mM NaCl) containing phosphatase inhibitor cocktail 1 (Sigma), protease inhibitor 
(ROCHE) and I mM phenylmethylsulfonyl fluoride (PMSF). Protein concentrations 
were quantified with the DC protein assay (Bio-Rad Laboratories, Veenendaal, the 
Netherlands) with bovine albumin as a standard. Equal amounts of protein were loaded 
onto polyacrylamide-SDS gels and after electrophoresis, proteins were transferred to a 
PVDF membrane. The membrane was blocked I h with 5% non-fat milk in PBST and 
probed with primary antibodies overnight at 4°C. The following primary antibodies 
were used: AMPKa (1:1000, Cell Signaling Technology); Phospho-AMPKa Thr172 
( I :500, Cell Signaling Technology); p-Akt (I :  I 000, Cell Signaling Technology); 
Phospho-GSK-3 (I:  1000, Cell Signaling Technology); Phospho-PKA (I :  1000, Cell 
Signaling Technology); Phospho-p38 ( I :  1000, Cell Signaling Technology); p38 
(1:1000, Cell Signaling Technology); MMP-9 (1 :1000, Abeam), collagen I ( 1 :1000, 
Abeam), TGFP-1 ( 1 :  1000, Abeam), Phospho-smad2/3 ( 1: 1000, Cell Signaling 
Technology); eNOS (1:1000, Cell Signaling Technology); GLUT4 (1:1000, Cell 
Signaling Technology); and GAPDH (I :20,000, Fitzgerald Industries International, 
Acton, Mass). Immunoblots were next processed with secondary antibodies for 1 hr at 




All data are presented as means ± s.e.m. Differences between groups were analyzed 
using one-way analysis of variance (ANOV A) follow by 2-sided Dunnett t-test as a 
post-hoc test, taking the ZDF group as a comparator. Differences were considered 
statistically significant if p<0.05. 
Results 
Biometric parameters, parameters of glucose metabolism 
No significant differences in body weight, heart weight, LV weight, LV weight and 
body weight ratio were found at the end of treatment period among all groups (Table 1). 
Plasma glucose levels and �nsulin levels were measured at baseline and 15 
weeks after vildagliptin treatment. At both time points, plasma glucose levels were 
significantly increased in ZDF rats compared to ZL rats, and no effects of DPP-4 
inhibition with vildagliptin were observed. We also observed hyperinsulinernia in 
treated and untreated ZDF rats compared to ZL rats at baseline; treatment with 
vildagliptin normalized plasma insulin levels in ZDF rats to levels comparable to those 
of ZL rats after 15 weeks of treatment. (Table I ). 
Plasma NEFA levels were reduced 40% in vildagliptin treated ZDF rats 
compared to untreated ZDF rats, although still 2-fold higher compared to ZL rats. 
Additionally, ZDF rats displayed significantly reduced plasma lactate levels compared 
to ZL rats while the plasma lactate levels appeared normal in the vildagliptin treated 
rats. In addition, glycogen content was significantly increased in ZDF rats, while a 
significant decrease of the myocardial glycogen content was found in the vildagliptin 
group (Table I). 
DPP-4 inhibition improved parameters of myocardial glucose metabolism in ZDF 
rats 
Next we assessed several parameters of myocardial glucose metabolism. First, we 
found that myocardial glycogen content was substantially increased, by 4-fold, in the 
untreated ZDF rats compared to ZL rats (Figure IA). The increase in myocardial 
glycogen content in untreated ZDF rats was associated with a significant reduction of 
phosphorylated (p-) GSK-3 and GLUT4 protein expression (Figures 1B and C) and 
also GLUT 4 mRNA levels (Figure ID). Vildagliptin-treated ZDF rats had a 
significantly reduced myocardial glycogen content compared to untreated ZDF rats 
(Figure IA), and restored expression levels of myocardial p-GSK-3 and GLUT4 
(Figures IB and C), however no effect was found on myocardial GLUT 4 mRNA 
levels (Figure ID). Lastly, we observed that untreated ZDF rats displayed significantly 
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higher myocardial mRNA levels of pyruvate dehydrogenase kinase isozyme 4 (PDK4) 
compared to ZL rats (Figure l E), which was partially reversed upon vildagliptin 
treatment. No differences were found in protein levels of p-AMPK, p-Akt and eNOS 
between all groups (Figure IF). Altogether, these data indicate that diabetes in ZDF 
rats is associated with distinct alterations in myocardial glucose metabolism and 
homeostasis in ZDF rats, and that DPP4-inhibition by vildagliptin largely reverses 
these changes. 
Table 1 General parameters 
Zucker+Lean ZDF ZDF+VIL 
N=7 N=7 N=7 
BW (15 week) (g) 387± 1 1  410± 19  409±8 
HW (g) 1.31±0.12 1.14±0.02 1. 1 8±0.04 
LVW (g) 0.92±0.09 0.82±0.01 0.86±0.03 
LVW/BW 2.36±0.18 2.00±0.07 2.12±0.08 
Glucose (15 weeks) 9.6±0.4 23.9± 1 .7 ** 21.5±2.4 ** 
(mmol/L) 
Insulin (15 weeks) 0.28±0.04 0.28±0.05 0.34±0.04 
(mmol/L) 
HbAcl (15 weeks) 3.57±0.04 9.54±0. 1 6  ** 9.00±0.20 ** 
HOMA index 0.69±0.07 8.72±1.80** 10.10±1.93** 
(Baseline) 
HOMA index 0.85±0.14 2.18±0.50* 2.28±0.41 * 
(15 weeks) 
NEFA (mmol/L) 143.3±29.4 494.4±72 * 308.6±55.9 
Lactate (mmol/L) 2.17±0.25 l .43±0.09 2.3 1±0.35 # 
Ketone bodies 0.77±0.14 1.07±0.15 0.82±0.10 
(mmol/L) 
Data are presented as means ± SEM; N indicates number of animals; BW, body weight; I IW: heart weight; 
LVW, left ventricle weight; LVW/BW, left ventricle weight / body weight ratio; HOMA index: 
Homeostasis Model Assessment. 
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Figure 1 Effects of vildagliptin on myocardial glucose metaboli m following 1 5  weeks treatment. A, 
Myocardial glucogen content. B and C, lmmunoblot analysis of Glycogen synthase kinase (GSK)-3� 
phosphorylation and glucose transporter type 4 (GLUT4) protein expressions. Levels of protein were 
quantified by densitometry and normalized against GAPDH as a loading control. D and E, GLUT4 and 
pyruvate dehydrogenase kinase isozyme 4 (PDK4) mRNA expression. Data are presented as fold change. E, 
Representative immunoblots of 5' adenosine monophosphate-activated protein kinase (AMPK) 
phosphorylation, Protein Kinase B (Akt) phosphorylation and endothelial nitric oxide synthase (eNOS) 
protein expressions. Values are means ± s.e.m. N 7, *P<0.05 vs. sham group; #P<0.05 vs. M l  group. 
Diabetes, DPP-4 inhibition by vildagliptin, and diastolic function. 
To more precisely investigate the myocardial alterations of diabetic cardiomyopathy 
and the effect of vildagliptin treatment herein, we then extensively assessed parameters 
of cardiac function. First, we observed abnormal filling velocities in untreated ZDF rats, 
as their early filling velocity (E) was significantly reduced compared to ZL rats (Figure 
2A). No differences between all groups were observed in the atrial filling phase (A) 
(Figure 2B). As a result, the early to late diastolic inflow velocity ratio (E/A ratio) was 
decreased (Figure 2C) in untreated ZDF rats compared to ZL rats. Vildagliptin 
treatment led to a trend to preservation of diastolic function (E, E/A ratio). We 
additionally show that the tissue velocity was significantly reduced in untreated ZDF 
compared to ZL rats. This reduction was non-significantly reversed by vildagliptin 
treatment (Figure 2D). Altogether, these parameters suggest an early manifestation of 
abnormal L V diastolic function. Contrary, systolic function was preserved in ZDF rats, 
as left ventricular fractional shortening was similar in all groups (Figure 2E). 
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Figure 2 Effects of vildagliptin on myocardial diastolic performance by echocardiographic assessment 
following 15 weeks treatment. A, Early fi lling velocity (E) was significantly reduced compared to Zucker 
lean rats B, No differences between all groups were observed in the atrial filling phase (A). C, Ratio of early 
to late d iastolic inflow velocity (E/A ratio) was decreased in untreated ZDF rats compared to ZL rats. 
Vi ldagliptin treatment led to a trend to preservation of diastolic function (E, E/A ratio). D, Tissue velocity 
imaging, means of septa! and lalcral wall, measured in apical 4 chamber view. E, Percent of fractional 
shortening (FS %). Data arc means ± s.c.m. N=7, *P<0.05 vs. sham group. 
Table 2 Hcmodynamic parameters 
Zucker+Lean ZDF ZDF+VIL 
N=4 N=7 N=6 
SBP (mmHg) 117±4 124±4 116±7 
DBP (mmHg) 71±4 79±4 69±6 
LVEDP (mmHg) 7.2±3.8 9.2±6.3 8.3±7.6 
Corrected dPdtmax 74±9 51±6* 61±5 
(mmHg/s) 
Corrected dPdtmin -57±9 -43±5 -51±4 
(mmHg/s) 
Data arc presented as means ± SEM; N indicates number of animals; LVESP, left ventricular end-systolic 
pressure; LVEDP, left ventricular end-diastolic pressure; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; corrected dP/dtmax and dP/dtmin, the maximal rate of increase and decrease of left 
ventricular pressure divided by systolic blood pressure, respectively. *P<0.05 vs. Zucker lean 
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Next we evaluated hemodynamic outcomes in ZDF rats treated or not treated 
with vildagliptin. Untreated ZDF rats had worse hemodynamic outcome compared with 
Zucker lean rats as demonstrated by a slightly elevated left ventricular end diastolic 
pressure and worse maximal rates of increase and decrease of left ventricular pressure 
( dP/dtmax and clP/dtmin) were both worse in ZDF rats compared to Zucker lean rats 
(Table 2). Vildagliptin treatment appeared to have no benefit in any of the 
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Figure 3 Effects ofvildagliptin on myocardial fibrosis following 15 weeks treatment. A. Representative 
photographs ofperivascular fibrosis indicated by Masson's trichrome staining (upper panel) and interstitial 
fibrosis indicated by Sirius red/fast green staining (middle panel). The lower panel shows polarized light 
photographs of interstitial fibrosis. B and C, Bar graphs to indicate the ratio of perivascular fibrosis to the 
whole vessel area and the volume of interstitial fibrosis. Data are means ± s.e.m. N=7, *P<0.05 vs. sham 
group; #P<0.05 vs. MI group. 
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DPP-4 inhibition decreases myocardial fibrosis in ZDF rats 
Next, we evaluated alterations in cardiac morphology and the effect of vilclagliptin 
treatment. Myocardial fibrosis and collagen deposition constitute the initial structure 
changes in diabetic hearts 22• Masson's trichrome staining and picrosirius red fast green 
staining both showed increased myocardial fibrosis in untreated ZDF rats (Figure 3A). 
DDP-4 treatment reduced both interstitial and perivascular fibrosis, by 50% and 30% 
respectively, compared to untreated ZDF rats (Figures 3B and 3C), reaching levels 
















ZL ZDF ZDF+VIL 
* * 
ZL ZDF ZDF+VIL 
ZL ZDF ZDF+VIL -
...,..._,,_� 
















ZL ZDF ZDF+VIL 
* 
# 
ZL ZDF ZDF+VIL 
ZL ZDF ZDF+VIL 
,__,_-.._..._....,_._ 
ZL ZDF ZDF+VIL 
Figure 4 Effects of vildagliptin on myocardial fibrosis protein expressions following IS weeks 
treatment. Representative immunoblots and bar graphs to indicate the changes of protein matrix 
metallopeptidase 9 (MMP-9, A), collagen-I (B), Transforming growth factor beta 1 (TGF�-1, C) and 
phosphorylation of smad2/3 (D). Data are means ± s.e.m. N=7, *P<0.05 vs. sham group; #P<0.05 vs. MI 
group. 
To further understand the antifibrotic effects of vilclagliptin treatment we then 
analyzed the mRNA and protein expression offibrotic factors. The pro-fibrotic proteins 
MMP-9 and collagen-I were both significantly increased in untreated ZDF rats 
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compared to ZL (Figure 4 A and B). Vildagliptin treatment led to significant reduction 
in collagen- I protein expression (Figure 4B); however no differences were found in 
MMP-9 protein levels (Figure 4A). The expression of other pro-fibrotic proteins, such 
as TGF-�l and p-smad2/3 appeared not to be increased in untreated ZDF rats, but were 
unaffected by vildagliptin treatment (Figures 4C and D). 
We then studied important stress pathways in cardiac remodeling. 
Phosphorylated PK.A was significantly decreased in ZDF compared to ZL rats, while 
vildagliptin treatment restored p-PKA levels (Figure SA). Furthermore, a significant 
increase level of p-P38 was observed in the hearts from ZDF rats, which was decreased 
by vildagliptin treatment (Figure SB). No differences of p-Erk were found among all 
groups (Figure SC). 
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Figure 5 Effects of vildagliptin on 
phosphorylation of PKA, P-38, and Erk 
protein expressions following 15 weeks 
treatment. Representative immunoblots and 
bar graphs of phosphorylation of protein kinase 
A (PKA, A), P38 mitogen-activated protein 
kinases (p-38, B) and extracellular-signal­
regulated kinase (Erk, C). Protein levels are 
normalized against total PKA, P-38 and Erk 
respectively. Data are means ± s.e.m. N=7, 
*P<0.05 vs. sham group; #P<0.05 vs. Ml 
JJT"Olln 
In this study we first characterized the cardiac phenotype in the ZDF rat, a rat model of 
diabetes mellitus, and second we tested the effects of the DPP4-inhibitor vildagliptin 
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on myocardial structure and function. We demonstrate here that the alterations in 
cardiac function of the ZDF rat are characterized by an impaired diastolic dysfunction, 
evidenced by lower E (and thus E/A ratio) and lower tissue velocity, indicative for 
early phase of diabetic cardiomyopathy. These unfavorable cardiac changes were 
associated with an increase of myocardial interstitial and perivascular fibrosis, 
production of pro-fibrotic factors, and changes in myocardial glycometabolic factors. 
We further demonstrate that factors, and changes in myocardial glycometabolic factors. 
We further demonstrate that treatment with the DPP-4 inhibitor vildagliptin exerted 
protective effects on cardiac function, since a trend of improvement of diastolic 
function was observed. Vildagliptin treatment partially reversed fibrosis, and, 
additionally, vildagliptin treatment appeared to beneficially affect fatty acid 
metabolism as demonstrated by the decrease in plasma NEFA levels in the treated ZDF 
rats. Quite surprisingly, vildagliptin had no clear effect on plasma glucose levels, and 
thus the beneficial effects of vildagliptin on cardiac function and structure in ZDF rats 
appear to be glucose-independent. 
We demonstrate diastolic dysfunction upon hyperglycemia in the ZDF model as 
evidenced by changes in L V filling (E, E/ A ratio) and TYi indicating early stage of 
diastolic function as seen in diabetic cardiomyopathy. Our observations of an impaired 
diastolic function and maintained systolic function in untreated ZDF rats arc altogether 
consistent with earlier research on cardiac abnormalities in diabetic cardiomyopathy 23• 
Increased LV diastolic stiffness and relaxation disturbances have been reported in both 
clinical and experimental studies before and have been found to be present in 27-70% 
of the diabetic patients 23• Given the explosion in type 2 diabetes mellitus, the 
associated cardiac abnormalities represent a major health care problem. 
Previous research had already demonstrated increased fibrosis in myocardium 
and impaired cardiac function due to long-term hyperglycemia in ZDF rats 24-26. Here 
we confirm these earlier studies by showing that the interstitial fibrosis in the 
myocardium was significantly increased in ZDF rats. This increase in interstitial 
fibrosis was further associated with an increase in collagen I mRNA and protein 
expression. Moreover, our findings parallel earlier studies on cardiac abnormalities 
under hyperglycemic conditions. It has previously been found that cardiac fibrosis 
induced by sustained hyperglycemia increases myocardial stiffness, prolongs atrial 
filling phase, and finally results in impaired LV relaxation 27. Myocardial fibrosis and 
collagen deposition arc the culprit mediators that initiate cardiac diastolic dysfunction, 
myocardial fibrosis and diabetic hearts has frequently been observed. For example, 
both interstitial and perivascular fibrosis were observed in diabetic patients by biopsies 
28 and experimental studies demonstrated increased fibrosis in the diabetic myocardium 
16• 24• 25• 29• 30. Moreover we extend earlier work and show that the increase in fibrosis 
and collagen deposition was accompanied by over expression of protein levels of the 
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pro-fibrotic proteins collagen I and extracellular matrix breakdown protein MMP-9. An 
earlier experimental study showing increased cardiac fibrosis in prediabetic OLETF 
rats suggested TGFP-I as the fibrotic mediator in this condition 9• However, we were 
not able to detect any differences in TGFP- I protein levels and its downstream target 
protein smad2/3 in this study. Phosphorylated PKA and p-38 were significantly 
changed in the ZDF myocardium. Vahtole et al. also reported that an increase in the 
phosphorylation of the p38 MAPK in the diabetic post-MI infarct myocardium, in 
Goto-Kakizaki rats 31 and streptozotocin (STZ)-induced type I diabetes mellitus 32. 
DPP-4 inhibitors are relatively new antidiabetic agents. The effect of DPP-4 inhibitors 
(including vildagliptin) is to inhibit the degradation of GLP-I ,  which has been shown 
to exert multiple protective effects on both pancreases and heart, including reduction of 
fibrosis 33 34• Thus we investigated whether vildagliptin treatment can protect from 
diabetic cardiomyopathy. In our study, we found that vildagliptin reversed interstitial 
and perivascular fibrosis, and these findings were associated with a significant 
decreased collagen I protein expression. In a recent study, Chaykovska showed that 
another DPP-4 inhibitor linagliptin has an antifibrotic effect demonstrated by elevation 
cardiac expression ofTGF-P l ,  TIMP-1 ,  COLLl A l  as well as COLL3AI mRNA levels 
35
• Phosphorylated PKA and p-38 were partially restored by the vildagliptin treatment, 
although without an effect of decreasing the MMP-9 protein expression. It has been 
suggested that p38 MAPK play a role to regulate myocyte apoptosis, cellular 
hypertrophy, cardiac fibrosis, and cardiac cytokine-mediated inflammation 32• 36• 
In addition to the structural changes in diabetic hearts, alterations in myocardial 
glucose metabolism have also been confirmed by many studies. The insulin-resistant 
ZDF rats represent numerous early path physiological changes in cardiac carbohydrate 
metabolism 37• It has been shown that high glycogen content, decreased glycogen 
synthase and low rate of glucose transport were present in the diabetic rat heart 16• 38. 
Specifically, hearts from ZDF rats have impaired lactate oxidation, without clear 
functional consequence 39. In our study, the ZDF animals manifest elevated glucose 
levels and insulin levels, suggesting the early phase of diabetes, since hyperinsulinernia 
is provoked by high glucose levels. At the end of the experiment, a reduction of insulin 
levels was found in our study, indicating that pancreatic beta bells cannot longer 
respond to high glucose levels, which showed a later phase of diabetes. However, 
vildagliptin treatment had no effects on systemic glucose and insulin levels. However, 
we found a significant increase of myocardial glycogen content in ZDF animals, 
consistent with a previous study 38, and vildagliptin treatment reduced the myocardial 
glycogen content in the ZDF rats. Furthermore, we also found that the significant 
increase of myocardial glycogen content was associated with a decline of 
phosphorylated GSK-3 and GLUT4 protein expression. Vildagliptin normalized 
glycogen content, glycogen synthesis and glucose transport which could all contribute 
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to an improved cardiac function. Furthermore, a significant elevation of NEFA plasma 
levels as well as a significant reduction of the lactate plasma levels was observed in 
ZDF rats. Vildagliptin trended to improve NEFA plasma level, demonstrating that 
vildagliptin may exert a beneficial effects on diabetic hearts mediated by fatty acid 
metabolism. 
Conclusion: We describe that myocardial metabolic, structural, and functional 
dysfunction exists in diabetic ZDF rats, characterized by increased glycogen content 
and changes in glucose-specific genes, and interstitial and perivascular fibrosis. 
Treatment with the DPP-4 inhibitor vildagliptin led to an improvement in cardiac 
fibrosis and myocardial metabolism resulting in improved cardiac diastolic function, 
independent from systemic glucose levels. DPP-4 inhibition may be useful in patients 
with diabetic cardiomyopathy, and future clinical studies should be designed to 
evaluate the effects of DPP-4 inhibitors on cardiac function. 
Competing interests 
The authors declare that they have no competing interests. 
Acknowledgements 
Ms. Yin is a recipient of a fellowship by the Graduate School for Drug Exploration 
GUIDE (University of Groningen, Groningen, the Netherlands). The study was 
supported by Angteq BV, Groningen, the Netherlands. The research from Dr. de Boer 
is supported by the Netherlands Heart Foundation (grant 2007T046) and the 
lnnovational Research Incentives Scheme program of the Netherlands Organization for 




I .  Lin Y, Sun Z. Current views on type 2 diabetes. J Endocrinol 20 1 0;204: 1 - 1 1 .  
2. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;1 1 5:32 1 3-3223. 
3. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the 
Framingham study. Am J Cardiol I 974;34:29-34. 
4. De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, Van Belle E, et al. Impact of 
diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart 
J 2004;25:656-662. 
5. Bell OS. Diabetic cardiomyopathy. Diabetes Care 2003;26:2949-295 1 .  
6. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BY, et al. The impact of 
diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the 
Strong I leart Study. J Am Coll Cardiol 2001 ;37: 1 943- 1 949. 
7. Falcao-Pires I, Goncalves N, Moura C, Lamego I, Eloy C, Lopes JM, et al. Effects of 
diabetes mellitus, pressure-overload and their association on myocardial structure and 
function. Am J Hyper/ens 2009;22: 1 1 90- 1 I 98. 
8. Brown RA, Fil ipovich P, Walsh MF, Sowers JR. Influence of sex, diabetes and ethanol on 
intrinsic contractile performance of isolated rat myocardium. Basic Res Cardiol 
1 996;91 :353-360. 
9. Mizushige K, Yao L, Noma T, Kiyomoto 1 1, Yu Y, l losomi N, et al. Alteration in left 
ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant 
prediabetic stage of a type II diabetic rat model. Circulation 2000;101 :899-907. 
1 0. Astorri E, Fiorina P, Contini GA, Albertini D, Magnati G, Astorri A, et al. Isolated and 
preclinical impairment of left ventricular filling in insulin-dependent and non-insulin­
dependent diabetic patients. Clin Cardiol I 997;20:536-540. 
1 1 . Joffe II, Travers KE, Perreault-Micale CL, Hampton T, Katz SE, Morgan JP, et al. 
Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: 
noninvasive assessment with doppler echocardiography and contribution of the nitric oxide 
pathway. J Am Coll Cardiol I 999;34:2 1 1 1 -2 1 1 9. 
1 2. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, et al. Leptin receptor 
missense mutation in the fatty Zucker rat. Nat Genet 1 996;13: 1 8- 1 9. 
1 09 
m 
Vildagliptin in diabetic cardiomyopathy 
1 3. Fredersdorf S. Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA, et al. 
Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty 
rats. Cardiovase Pathol 2004;13 : 1 1 - 1 9. 
1 4. Nunoda S, Genda A, Sekiguchi M, Takeda R. Left ventricular endomyocardial biopsy 
findings in patients with essential hypertension and hypertrophic cardiomyopathy with 
special reference to the incidence of bizarre myocardial hypertrophy with disorganization 
and biopsy score. 1/eart Vessels 1 985;1 : 1 70- 1 75. 
1 5 .  Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS .  Defective sarcoplasmic reticular calcium 
transport in diabetic cardiomyopathy. Am J Physiol 1 983;244:E528-35. 
1 6. van den Brom CE, I luisman MC, Vlasblom R, Boontje NM, Duijst S, Lubbcrink M. et al. 
Altered myocardial substrate metabolism is associated with myocardial dysfunction in early 
diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovase 
Diabetol 2009;8:39. 
1 7. Ocscburg I I, de Boer RA, Buikema H, van der 1 -Iarst P, van Gilst WI I, Si llje I II I. Glucagon­
likc peptide I prevents reactive oxygen species-induced endothelial cell senescence through 
the activation of protein kinase A. Arteriosc/er Thromb Vase Biol 20 1 0;30 : 1407- 14 14. 
1 8. Matthews DR, I Iosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. I Iomcostasis 
model assessment: insulin resistance and beta-cell function from fasting plasma glucose and 
insulin concentrations in man. Diabetologia I 985;28:4 1 2-4 1 9. 
1 9. Wcstcnbrink BD, Ruifrok WP, Voors AA, Tilton RG, van Vcldhuisen DJ, Schoemaker RG, 
et al. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement 
of cardiac function in heart failure. Cardiovase Res 20 1 0;87:30-39. 
20. Yin M, Sillje I II I, Meissner M, van Gilst WI I, de Boer RA. Early and late effects of the 
DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. 
Cardiovase Diabetol 20 1 1  ;10:85. 
2 1 .  Yin M,  van der I Iorst IC, van Melle JP, Qian C, van Gilst W I  I, Sillje I 1 1-1, et al. Metformin 
improves cardiac function in a non-diabetic rat model of post-M I heart failure. Am J Physiol 
I /earl Cire Physiol 20 1 1  ;. 
22. Falcao-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular 
and cellular basis to progress in diagnosis and treatment. I /earl Fail Rev 20 1 1 ;. 
23. Voulgari C, Papadogiannis D, Tentolouris N. Diabetic cardiomyopathy: from the 
pathophysiology of the cardiac myocytcs to current diagnosis and management strategies. 
Vase I lea/th Risk Manag 20 I 0;6:883-903. 
1 1 0 
Chapter 5 
24. Forcheron F, Basset A, Abdallah P, Del Carmine P, Gadot N, Beylot M. Diabetic 
cardiomyopathy: effects of fenofibrate and metformin in an experimental model--the 
Zucker diabetic rat. Cardiovasc Diabetol 2009;8: 1 6. 
25. Huang TH, Yang Q, Harada M, Li GQ, Yamahara J, Roufogalis BD, et al. Pomegranate 
flower extract diminishes cardiac fibrosis in Zucker diabetic fatty rats: modulation of 
cardiac endothelin- 1 and nuclear factor-kappaB pathways. J Cardiovasc Pharmacol 
2005;46:856-862. 
26. Marsh SA, Powell PC, Agarwal A, Dell'Italia LJ, Chatham JC. Cardiovascular dysfunction 
in Zucker obese and Zucker diabetic fatty rats: role of hydronephrosis. Am J Physiol Heart 
Circ Physiol 2007;293:H292-8. 
27. Jain A, Avendano G, Dharamsey S, Dasmahapatra A, Agarwal R, Reddi A, et al. Left 
ventricular diastolic function in hypertension and role of plasma glucose and insulin. 
Comparison with diabetic heart. Circulation 1 996;93: 1 396- 1402. 
28. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, et 
al. Diastolic stiffiless of the failing diabetic heart: importance of fibrosis, advanced 
glycation end products, and myocyte resting tension. Circulation 2008;1 1 7:43-5 1 .  
29. Ares-Carrasco S, Picatoste 8, Benito-Martin A, Zubiri I, Sanz AB, Sanchez-Nino MD, et al. 
Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term 
experimental diabetes. Am J Physiol Heart Circ Physiol 2009;291:1-12 1 09- 1 9. 
30. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, et al. Contributions of 
inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic 
cardiomyopathy: the role of angiotensin type I receptor antagonism. Diabetes 2007;56:64 1 -
646. 
3 1 .  Vahtola E, Louhelainen M, Forsten H ,  Merasto S, Raivio J ,  Kaheinen P, et al. Sirtuin l -p53, 
forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic 
Goto-Kakizaki rat. Cardiovasc Diabetol 201 0;9:5. 
32. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bucker-Gartner C, Sobirey M, et 
al. Inhibition ofp38 mitogen-activated protein kinase attenuates left ventricular dysfunction 
by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes 
mellitus. Diabeto/ogia 2006;49:2507-25 1 3. 
33. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3 : 1 53- 1 65. 
34. Robinson E, Cassidy RS, McDermott BJ, Green BD, Grieve DJ. 49 Glucagon-like peptide­
) protects against cardiac remodelling after myocardial infarction via specific actions on the 
extracellular matrix. Heart 201 1 ;97:e7. 
1 1 1  
Vildagliptin in diabetic cardiomyopathy 
35. Chaykovska L, von Websky K, Rahnenfuhrer J, Alter M, Heiden S, Fuchs I I, el al. Effects 
of DPP-4 Inhibitors on the I leart in a Rat Model of Uremic Cardiomyopathy. PloS One 
20 I I ;6:e2786 I .  
36. Li M, Georgakopoulos D, Lu G, I lester L, Kass DA, I lasday J, el al. p38 MAP kinase 
mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix 
remodeling in heart. Circulation 2005;1 1 1  :2494-2502. 
37.  Chatham JC, Seymour AM. Cardiac carbohydrate metabolism in Zucker diabetic fatty rats. 
Cardiovasc Res 2002;55: 1 04- 1 1 2. 
38 .  Lajoie C, Calderone A, Trudeau F,  Lavoie N, Massicotte G, Gab'llOn S ,  et al. Exercise 
training attenuated the PKB and GSK-3 dephosphorylation in the myocardium ofZDF rats. 
J Appl Physiol 2004;96: 1 606- 1 6 1 2. 
39. Wang P, Lloyd SG, Zeng 1 1, Bonen A, Chatham JC. Impact of altered substrate utilization 
on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am J Physiol Heart 
Circ Physiol 2005;288:1 12 1 02- 1 0. 
1 12 
Chapter 6 
Diabetes is associated with an increased incidence of 
non-ischemic heart failure in patients with coronary 
artery disease 
B. Daan Westenbrink, MD PhD, Meimei Yin, Rudolf A. de Boer, MD PhD, J. Herre Kingma, 
MD PhD, Wayne J. Warnica, MD, Richard Bai/lot, MD, Jean L. Rouleau, MD PhD and Wiek H. 
van Gilst, PhD.for the IMAGINE investigators 
From the Department of Cardiology, University Medical Center Groningen, Groningen, the 
Netherlands (BDW, MY, RAB, WHO), Medisch Spectrum Twente, Enschede, the Netherlands 
(JHK), Foothills Hospital, University of Calgary, Canada (WJW), Hospital Laval, Laval 
University, Canada (RB)and Institut de Cardiologie de Montreal, University of Montreal, 
Montreal, Canada (JLR). 
Chapter 6 
Abstract 
Aim: To determine whether diabetes is associated with an increased incidence of heart 
failure after coronary artery bypass grafting (CABG), and whether this can be 
explained by the recurrence of coronary ischemia. 
Methods and results: We retrospectively analysed prospectively collected data from 
the IMAGINE trial, which tested whether early post-operative initiation of quinapril 
after CABG would reduce cardiovascular events in stable low risk patients with normal 
cardiac function. Of the 2553 patients included in the IMAGINE trial, 253 (10%) had 
diabetes (HBAlc 6.8 ± 1.2 %), of which 1 51 (60%) were treated with mctformin and 
6 1  (24%) with insulin. During the maximal follow up of 43 months, the incidence of 
Major Adverse Coronary Events (MACE), coronary revascularisations or a composite 
of all cause cardiac and cerebrovascular events was comparable between diabetic and 
non-diabetic patients. Diabetes was, however, associated with a 3-fold higher incidence 
of hospitalizations for heart failure (adjusted hazard ratio (adj. HR) 3. 1 3, 95% 
confidence interval (Cl) 1.36-7. 19, p=0.007). A MACE never preceded heart failure 
hospitalisations in patients with diabetes and the incidence of recurrent ischemia was 
lower than in non-diabetic patients (HR 0.48, 95%CI (0.25-0.95), p=0.034). The use of 
mctformin was associated with a trend towards reduced heart failure hospitalisations 
within the subgroup of diabetic patients (adj. HR 0.27, 95% CI (0.1-1. 1 ), p=0.067). 
Conclusions: Diabetes is associated with an increased incidence of non-ischemic heart 
failure in patients with coronary artery disease. 
Key words: Coronary artery bypass grafting, diabetes, heart failure, mctformin 
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Introduction 
Diabetes is associated with a two-fold higher lifetime risk of heart failure l-4_ Although 
diabetes predisposes to multiple other risk factors for heart failure, these cannot fully 
explain the high incidence of heart failure in patients with diabetes 5• It has thus been 
hypothesized that diabetes causes a distinct, "diabetic" cardiomyopathy 6• 
Diabetes is also a classical coronary risk factor associated with more extensive 
coronary artery disease (CAD), frequent revascularisation procedures and a higher 
incidence of Major Adverse Coronary Events (MACE) after revascularisation 7• 8• 
These coronary sequelae of diabetes are plausible explanations for the development of 
heart failure and diabetic cardiomyopathy is therefore defined as heart failure 
developing in the absence of CAD 6• However, if heart failure can result from a 
diabetes-specific pathology in patients without CAD, there is no compelling reason 
why this could not also affect diabetic patients with CAD. We therefore hypothesise 
that diabetic cardiomyopathy may also develop in diabetic patients with established 
CAD. 
We evaluated whether diabetes was associated with an increased incidence of 
heart failure after Coronary Artery Bypass Grafting (CABG) and whether the 
development of heart failure is associated with the recurrence of ischemia or MACE. 
For this purpose we examined the contemporary IMAGINE (Ischemia Management 
with Acupril post bypass Graft via Inhibition of the coNverting Enzyme) trial database 
of2553 low risk patients undergoing CABG 9• J O_ 
Methods 
The design of the IMAGINE trial, has been described in detail previously 9, as well as 
the results of the main study J O_ In brief, the IMAGINE study was a double-blind, 
placebo-controlled, parallel-group, randomized, multicenter international trial 
conducted in patients who underwent CABG surgery between November 1 999 and 
September 2004. The main goal of the study was to test whether early initiation of an 
ACE inhibitor after CABG (initiated within the hospital phase) would reduce the rate 
of cardiovascular events in patients at relative low risk. The ethics committees of all 
participating institutions approved the research protocol and all patients provided 
written informed consent. 
Patients 
Patients were screened for eligibility within 4 weeks of surgery or following surgery 
and randomized within 7 days after CABG except for patients included in France 
(N=235, 9.1%), where randomization occurred within 10 days after CABG. Treatment 
consisted of the ACE inhibitor, quinapril, with forced up titration to 40 mg daily within 
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4 months if tolerated, or matching placebo. Due to increasing evidence for the benefit 
of ACE inhibitors in patients with diabetes, all patients on insulin and diabetic patients 
with rnicroalbuminuria were no longer eligible for the study starting November 2001. 
The final sample size of the IMAGINE study was 2553 patients. 
Endpoints 
We used the same primary and secondary endpoint of the IMAGINE trial, an 
additional composite endpoint of Major Adverse Cardiac Events (MACE) and, 
furthermore, considered all individual endpoints separately. The primary endpoint was 
a composite of cardiovascular death or resuscitated cardiac arrest, nonfatal myocardial 
infarction, coronary rcvascularization, unstable angina that required hospitalization, 
documented angina that did not require hospitalization, stroke and congestive heart 
failure that required hospitalization. The pre-specified secondary endpoint was a 
composite of the primary end point with the addition of transient ischemic attack and 
any other cardiovascular event that required hospitalization. MACE was defined as 
cardiovascular death, resuscitated cardiac arrest, unstable angina or myocardial 
infarction. 
Statistical analysis 
Data arc given as means ± standard deviation (SD) when normally distributed, as 
median and interquartile range (IQR) in case of skewed distribution and as frequencies 
and percentages for categorical variables. Differences in variables between groups 
were compared with student T-tcst, Mann Whitney-U test, x2 test or Fishers exact test, 
where appropriate. Differences between the diabetic and the non-diabetic groups were 
estimated as a hazard ratio (HR) with associated adjusted two-sided 95% confidence 
interval (Cl) from a Cox proportional hazards regression model, that included the 
effects of age, gender, treatment assignment, diabetic and cardiovascular medications, 
left ventricular ejection fraction (L VEF), smoking status, systolic and diastolic blood 
pressure, creatinine values, history of hypertension / percutaneous coronary 
interventions / myocardial infarction / previous CABG surgery and stroke, vessel 
disease, completeness of revascularization ( defined as complete when all vessels > I 
mm with a stenosis >70% were bypassed) and beating heart (off pump) surgery. 
Because we recently showed that mctformin attenuates heart failure development after 
myocardial infarction in an experimental model 1 1 , we also evaluated the effect of 
mctformin on the incidence of heart failure within the subpopulation of patients with 
diabetes, controlling for the use of insulin, pre-operative left ventricular ejection 
fraction, history of myocardial infarction and hypertension. Cumulative event rate 
were calculated by the Kaplan Meier method and displayed graphically. All statistical 
analysis was performed using SPSS, Chicago version 18.0. 
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Results 
Demographics of the study population 
Of the 2553 patients included in the IMAGINE trial, 1 0% had a history of diabetes, of 
which 151 (60%) were treated with metformin and 61 (24%) with insulin. 
Demographics of the population according to the presence of diabetes are given in 
Table 1 .  Patients with diabetes were significantly younger, more often female and had 
higher baseline systolic blood pressures and a history of hypertension more often than 
non-diabetic patients. All other demographics were comparable between diabetic and 
non-diabetic patients. 
Effect of diabetes on the incidence of cardiovascular events after CABG 
The median follow up time was 2.95 years. During this period, diabetes was not 
associated with an increased incidence of the primary or secondary IMAGINE 
endpoints or MACE (table 2). When the individual endpoints were considered 
separately, patients with diabetes displayed a significant higher incidence of heart 
failure requiring hospitalisation (table 2, figure 1)  and a reduced incidence of 
documented angina not requiring hospitalisation (table 2). All other component 
endpoints were comparable between patients with or without diabetes. 
Exploration of heart failure and cardiovascular events in diabetic subpopulation 
In patients with diabetes, a MACE never preceded hospitalization for heart failure and 
only one diabetic patient developed a MACE after heart failure had developed. 
Randomisation to quinapril did not affect the incidence of heart failure hospitalisations 
or other component or individual endpoints. In diabetic patients treated with metformin, 
there was a trend towards reduced heart failure hospitalisations, even after controlling 
for the concomitant use of insulin, pre-operative left ventricular ejection fraction, 
history of myocardial infarction and hypertension (adj. HR 0.27 95% CI (0.1-1.1), 
p=0.067). 
Discussion 
In the current analysis of low risk patients with normal cardiac function after scheduled 
CABG, diabetes was associated with a 3-fold higher incidence of hospitalisations for 
heart failure. Surprisingly, heart failure in patients with diabetes developed without the 
recurrence of ischemia or a preceding MACE. In fact, patients with diabetes had fewer 
ischemic events than non-diabetic patients. These findings suggest that diabetic 
patients may develop heart failure of non-ischemic origin that is not directly linked to 
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vascular events, even when they have already developed severe CAD. 
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Figure 1 .  Kaplan-Meier analysis of the cumulative incidence of heart failure hospitalisations 
according to the presence or absence diabetes. HR, Hazard Ratio; 95% Cl, 95 percent confidence interval 
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Figure 2. Kaplan-Meier analysis of the cumulative incidence of heart failure hospitalisations in 
patients with diabetes, according to the use of metformin. HR. Hazard Ratio; 95% CI, 95 percent 
confidence interval 
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0 Table 2. Incidence of the primary and secondary endpoints and their components in diabetic compared to non-diabetic patients 
Unadjusted Adjusted 
Variable Non- Diabetic HR (95%CD p HR (95%CI) p 
diabetic (n=253) 
(n=2300) 
Primary composite endpoint 295 ( 1 3) 35 ( 1 3) 1 .41  (0.54- 1 2.5) 0.234 
Secondary composite endpoint 453 (20) 57 (23) 1 .07 (0.08- 1 .42) 0.6 1 6  
Major Adverse Cardiac Events 1 3 1 (5.7) I 8 (7. 1 )  1 .22 (0.75-2.00) 0.425 
All cause mortality or resuscitated arrest 34 ( 1 .5) 3 ( l .2) 0.78 (0.24 1 -2.55) 0.687 
Acute coronary syndromes 1 00 (4.3) 1 5  (5.9) 1 .33 (0. 78-2.30) 0.506 
Coronary revascularization 84 (3. 7) 9 (3.6) 0.95 (0.48- 1 . 90) 0.893 
HF requiring hospitalization 20 (0.9) 1 1  (4.3) 4.09 ( 1 .86-8.99) <0.000 1 3 . 1 3  ( l .36-7. 1 9) 0.007 
Documented angina 1 63 (7. 1 )  9 (3 .6) 0.49 (0.25-0.96) 0.039 0.48 (0.25-0.95) 0.035 
Stroke or TIA 44 ( 1 .9) 4 ( 1 .6) 0.8 1 (0.29-2.25) 0.683 
Other CV hospitalizations 1 74 (8) 29 ( 12) 1 .54 ( 1 .04-2.28) 0.033 
CHF, congestive heart failure; TIA, transient ischemic cerebrovascular attack, CV; cardiovascular, HR, hazard ratio, 95%CI, 95% confidence interval, Adjusted for, age, 
gender, treatment assignment, days after CABG-surgery, baseline medications, left ventricular ejection fraction, systolic and diastolic blood pressure, creatinine, h istory of 
hypertension / percutaneous coronary interventions I myocardial infarction I previous CABG surgery / peripheral vascular disease I stroke, number of distal anastomosis, 
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Diabetes is a potentially modifiable coronary risk factor that is rapidly emerging. 
Approximately 80% of patients with diabetes will develop a myocardial infarction and 
a high percentage of them will undergo a coronary revascularisation procedure during 
their lifetime 7• 8• 1 2• Furthermore, the recurrence of cardiovascular events and restenosis 
rates are also markedly higher in diabetic than in non-diabetic patients 8• From the 
burden of CAD in diabetic patients, it does not appear surprising that diabetes is 
associated with an increased incidence of heart failure. Indeed, a recent study showed 
that while the association between diabetes and heart failure was independent of over 
65 potential confounders, heart failure in patients with diabetes still predominantly 
developed after a myocardial infarction 5• 
In the current analysis, heart failure after CABG developed in diabetic patients 
in the absence of new coronary events or recurrent ischemia. Furthermore, the 
increased incidence of heart failure was also independent of other risk factors for heart 
failure, including history of myocardial infarction and hypertension, LVEF and renal 
function, suggesting that heart failure was caused by a distinct diabetes related process. 
It therefore appears that diabetic cardiomyopathy can also develop in patients with 
severe CAD. Thus, while our analysis does not dispute that CAD can cause heart 
failure in diabetes; it does show that the mere presence of CAD in a diabetic patient 
does not necessarily explain the aetiology of heart failure. If our findings are be 
substantiated by other reports in the future, this would also implicate that the definition 
of diabetic cardiomyopathy should be revised. 
The current analysis was not adequately powered to conclusively identify factors 
that modulate the incidence of heart failure in patients with diabetes. In an exploratory 
analysis, however, we observed an interesting trend towards reduced heart failure in 
patients treated with metformin. Several epidemiological studies have associated 
metformin with a reduced event rate in patients with diabetes 13 • Moreover, a recent 
study from our group showed that metformin attenuated heart failure after myocardial 
infarction in rats without diabetes 1 1 • Metformin may thus have the potential to prevent 
heart failure in diabetic patients. Given the limitations stated above, these results 
should be interpreted with caution. Nevertheless, it does merit further investigation. 
Limitations 
The IMAGINE study involved a relatively healthy low risk population and patients 
with severe or complicated diabetes were specifically excluded from our study. While 
this could be regarded a strength of the study, it does also limits the ability to extend 
our findings to the general CABG population. Moreover, the fact that diabetes was not 
associated with an increased incidence of the other individual or composite endpoints, 
at least partially reflects the low event rate in the IMAGINE trial. Patients with clinical 
heart failure and systolic left ventricular dysfunction were excluded from IMAGINE, 
12 1 
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but we cannot exclude that some patients might have had pre-operative diastolic 
dysfunction that influenced the propensity to be hospitalised for heart failure. Finally, 
despite the use of extensive multivariable adjustments, we cannot be certain that the 
relation between diabetes and non-ischemic heart failure is causal since we employed a 
retrospective analysis of prospectively collected data. Future studies are needed to 
further define the prevalence of diabetic cardiomyopathy in patients with CAD 
undergoing CABG. 
Conclusions 
Diabetes is associated with an increased incidence of non-ischemic heart failure in 
patients with coronary artery disease. The cause for heart failure hospitalizations in the 
diabetic subset of the IMAGINE population seemed mostly non-ischemic, which points 
towards the possibility that direct diabetic factors provoke heart failure development. 
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Summary 
Heart failure is characterized by cardiac dysfunction, severe symptoms and is 
associated with major morbidity and mortality 1 , and health care costs. The triggers that 
stimulate the development of heart failure are diverse, such as coronary artery disease, 
hypertension, dilated cardiomyopathy, valvular disease or diabetes 2• Diabetes has 
increased dramatically as a risk factor for coronary artery disease which can lead to 
myocardial infarction and subsequently to heart failure. Despite the diverse causes of 
heart failure, the clinical progression and underlying mechanisms share a common 
pathway. After cardiac injury, the heart starts to hypertrophy and reshapes as a 
response to injury, this process is called cardiac remodeling 3• Although 
pharmacological treatment has already achieved significant improvement, the outcome 
for heart failure patients is still poor. New therapeutically strategies on heart failure are 
therefore needed. 
In  chapter 1, we discuss the relationship between heart failure and diabetes. 
The most important conclusion is that diabetes and heart failure are both major and 
growing public health issues. In addition, they are strongly interrelated and can affect, 
aggravate and provoke each other. 
In chapter 2, we provide an overview of the available data from experimental 
studies evaluating the effect of oral diabetic medication on cardiac remodeling and 
heart failure. It is concluded that some anti-diabetic drugs, especially metformin and 
agents interfering with the GLP-1/DPP-4 system, exert cardioprotection, independent 
of their effect on glucose metabolism, in various experimental models. For metformin, 
this is supported by post hoc analyses from clinical trials. No prospective trials have 
been conducted specifically evaluating heart failure outcomes with antidiabetic 
treatment. We propose that these studies should be performed in diabetic, but even 
more interestingly, in pre-diabetic subjects. 
In chapter 3, we evaluated whether the first line anti-diabetic drug, metformin, 
would exert protective effects on cardiac remodeling in a post-Ml rat model. In this 
well-established experimental heart failure model, approximately 40% of the LV wall 
is infarcted, which is associated with a significant increase of ANP. Echocardiographic 
and hemodynamic parameters showed that, in control rats, cardiac function was 
remarkably reduced long term (10-12 weeks) after myocardial infarction, and left 
ventricular wall thinning, dilatation, and reduced systolic function was observed. 
Concomitantly, cardiac hypertrophy developed after myocardial infarction, evidenced 
by enlarged cardiomyocytes, and a significant decrease of capillary density. 
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Metformin treatment resulted in a moderate decrease in infarct size, and 
attenuation of cardiac remodeling, as evidenced by decreased ANP mRNA expression, 
improvement of systolic function and less left ventricular dilatation as compared to 
untreated myocardial infarction. In addition, molecular analyses suggested that altered 
AMPK phosphorylation status and low insulin levels could be the mechanisms 
underpinning the observed cardioprotection in this non-diabetic post-Ml animal model. 
We, furthermore, evaluated whether long-term heart failure would provoke insulin 
resistance. However, fasting glucose levels and the pattern of the oral glucose tolerance 
test suggested that no insulin resistance did occur during cardiac remodeling, and 
metformin did not affect this. Altogether, our results indicate that metformin has the 
potential to attenuate heart failure development after myocardial infarction in the 
absence of diabetes, independent of systemic glucose levels, and independent from 
insulin intolerance. 
In chapter 4, we investigated the effect of the DPP-4 inhibitor, vildagliptin, on 
post-Ml cardiac remodeling. Vildagliptin is a member of a new class of anti-diabetic 
drugs, the incretins, which are reported to have a beneficial role on the cardiovascular 
system. DPP-4 breaks down rapidly GLP-1, and a DPP-4 inhibitor prevents this to 
occur and thus raises GLP- 1 levels. We, therefore, hypothesized that the DPP-4 
inhibitor, vildagliptin, would also have a protective effect on cardiac function in post­
MI heart failure model. 
We used the same well-established rat post-Ml heart failure model as in chapter 
3. The DPP-4 inhibitor, vildagliptin, increased endogenous active GLP-1 levels 
approximately 3 -fold, associated with an (expected) inhibition of 70% in DPP-4 
activity. However, the infarct size and cardiac function did not differ between DPP-4 
inhibitor treated animals and controls. All other measures of cardiac remodeling were 
also not affected. The reasons for the failure of DPP-4 inhibition to halt adverse cardiac 
remodeling may be various: the dosing regimen, the different analogue utilized, the 
levels of G LP- I achieved, and the timing of the treatment and the species studied. 
These findings indicate, that despite an increase in plasma GLP- 1 levels by inhibiting 
DPP-4 activity, long-term treatment with the DPP-4 inhibitor, vildagliptin, does not 
afford cardiac protection in a rat post-Ml model of heart failure. 
In chapter 5, we explored the effect of the DPP-4 inhibitor, vildagliptin, on the 
early stage of diabetic cardiomyopathy. Since the incidence of diabetes is on the rise, 
we expect to see more often myocardial dysfunction in diabetic subjects, also in the 
absence of CAD or hypertension. Currently, only few data are available showing what 
effects are conferred by specific anti-diabetic treatment with respect to myocardial 
function and metabolism. We used Zucker Diabetic Fatty (ZDF) rats, which have a 
mutation in the leptin receptor gene, associated with obesity and diabetes, to study the 
myocardial changes and mechanisms pertinent to the metabolic syndrome. The animals 
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develop insulin resistance in the beginning of the study (age of 10 weeks), evidenced 
by increased glucose and insulin levels. In the following 15 weeks of the experiment, 
insulin levels in the ZDF animals decreased significantly, indicating pancreatic 
function failure. 
In this experiment, the heart of ZDF animals showed impaired diastolic function, 
altered myocardial metabolism, and myocardial fibrosis. The echocardiographic 
function parameters E, E/A ratio, and TVI were significantly decreased in the ZDF 
group compared to the Zucker lean animals, which served as control. These changes 
were associated with more collagen deposition, both interstitial as perivascular, which 
is consistent with an increased collagen I protein expression. P-38 MAPK and p-PKA 
were identified as potential contributors to the myocardial dysfunction and fibrosis. 
Alterations in myocardial substrate metabolism were also found in the present study, 
including abnormal lipid metabolism and glucose homeostasis. Increased NEFA were 
present in the ZDF animals, and myocardial glycogen content was significantly 
increased as well. The elevated glycogen content resulted in attenuation of 
phosphorylation of GSK-3 and GLUT4. Vildagliptin treatment attenuated myocardial 
fibrosis and left ventricular stiffness in diabetic animals, which led to a trend towards 
improvement of diastolic function. These changes were associated with a decrease of 
collagen I and of p-38 protein expression. Improved glucose metabolism was suggested 
by the observation of restored myocardial glycogen content and increased 
phosphorylation of GSK-3 and GLUT4 protein, which suggests that vildagliptin 
improves glucose uptake in the diabetic animal model. 
In chapter 6, we evaluated whether diabetes was associated with an increased 
incidence of heart failure after coronary artery bypass grafting (CABG) in the 
IMAGINE (lschemia Management with Acupril post bypass Graft via Inhibition of the 
coNverting Enzyme) trial. IMAGINE was a double-blind, placebo-controlled, 
randomized, multicenter international trial evaluating whether an ACE inhibitor, 
quinapril, administered early after CABG could reduce cardiovascular mortality and 
morbidity. From the 2553 patients, 10% had diabetes, of which 60% were treated with 
metformin and 24% were treated with insulin. During a median follow up of 
approximately three years, the incidence of the primary ( composite of cardiovascular 
death or resuscitated cardiac arrest, nonfatal myocardial infarction, coronary 
revascularization, unstable angina that required hospitalization, documented angina 
that did not require hospitalization, stroke and congestive heart failure that required 
hospitalization) and secondary ( of the primary end point with the addition of transient 
ischemic attack and any other cardiovascular event that required hospitalization) 
IMAGINE endpoints or major coronary events were comparable between the diabetic 
and non-diabetic patients. However, a 3-fold higher incidence of hospitalisation due to 
heart failure was observed in diabetic patients. Furthermore, there was a trend towards 
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reduced heart failure hospitalisations in diabetic patients treated with metformin, 
suggesting a protective potential on heart failure in diabetes. 
Future perspectives 
Diabetes and heart failure are very prevalent and it has been demonstrated that they 
affect each other mutually. As we know, many diseases are not isolated, stand alone 
problems. This is true for obesity, hypertension, metabolic syndrome, and thus also for 
diabetes and heart failure. This condition can be described as a cardiometabolic 
syndrome, as these two diseases can aggravate and provoke each other; i.e. patients 
with diabetes have a high risk to develop cardiovascular disease and subsequent heart 
failure, and in reverse order, heart failure patients with diabetes have worse outcome. 
For this reason, the cardiometabolic syndrome has become an important new target for 
research and treatment in cardiology during the last decade. However, there are very 
few studies that looked into the two diseases together. Therefore, it is mandatory to 
perform further clinical studies to focus on this cardiometabolic syndrome, enrolling 
patients with both diabetes and heart failure. 
In addition, both clinical studies and experimental studies have shown that 
diabetes specific treatment may be useful not only to correct glucose levels, but also to 
beneficially affect the heart directly. Our experimental study showed that metformin 
attenuates cardiac remodeling in the post-Ml, non-diabetic heart failure model 4. Based 
on this experimental study, we hypothesized that metformin has a potential beneficial 
effect in non-diabetic patients with left ventricular dysfunction. Therefore, we designed a!t 
and started a phase IV clinical trial that is called "Metformin to Reduce Heart Failure Ill 
After Myocardial Infarction" (GIPS-lll, NCT01217307). This study is still ongoing 
and will evaluate the effect of metformin in non-diabetic patients after myocardial 
infarction. Non-diabetic patients following ST-elevation myocardial infarction are 
selected and given metformin 500 mg twice daily during 4 months. The primary 
outcome is the effect of metformin treatment on left ventricular ejection fraction. The 
incidence of cardiovascular events during follow-up is the secondary outcome. 
Finally, over the years many experimental studies have reported protective 
effects of anti-diabetic drugs on the cardiovascular system. The majority of these 
studies were performed in non-diabetic animals, as reviewed in this thesis. In contrast 
however, the relatively small number of clinical trials performed so far, have been 
mostly negative or controversial in their findings s-s when compared to the reported 
experimental data. The explanation for this controversy is largely unknown but it 
stresses the importance of confirmative large clinical trials. Certainly for the newer 
anti-diabetic drugs like GLP-1 analogues and DPP-4 inhibitors, there are promising 
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and consistent results available from experimental studies outlining their 
cardioprotective potential but again large clinical trials are needed. The investment in 
this research will help our understanding of the mechanism of action of these drugs and 
certainly will generate new insight in the interplay between diabetes and heart failure. 
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Samenvatting en toekomstperspectieven 
Samenvatting 
Hartfalcn wordt gckarakteriscerd door cardiale dysfunctie en ernstige symptomen en is 
gcassocicerd met hoge morbiditeit, mortaliteit 1 , en hoge ziektekosten. Hartfalen kan 
door diverse triggers worden veroorzaakt; hartfalen kan onder andere opgewekt 
wordcn door aandoeningen van de kransslagaders (myocardinfarct), hypcrtensie, 
gcdilatccrdc cardiomyopathie, klcplijden en diabetes 2• Ondanks de vcrschillende 
oorzakcn van hartfalen, is het klinisch beloop ongeveer hctzelfdc en zijn ook de 
ondcrliggcndc mechanismcn van zickteprogressie veelal gelijk. Na hct ontstaan van 
schadc aan hct hart wordt het hart groter (hypertrofie) en verandert het hart als rcactic 
op de ontstane schade. Dit proces wordt remodeling genoemd3 • Hoewel 
farmacologische behandeling heeft geleid tot een aanzienlijke verbetering is de 
prognosc voor patientcn met hartfalen nog steeds slecht. Nieuwe therapeutische 
strategiccn zijn daarom noodzakclijk. 
Diabetes is een thans veelvoorkomende risicofactor voor coronaire hartziekte, welke 
kan leiden tot een hartinfarct en vervolgcns tot hartfalcn. Diabetes hccft ccn reciprokc 
relatie met hartfalen: diabetes vergroot de kans op het ontwikkclcn van hartfalen, maar 
patienten met hartfalen krijgen ook vaker diabetes. Als ccn van bcidc condities ontstaat 
als de andcr reeds aanwczig is, is het prognostischc effect hicrvan grater dan je zou 
verwachtcn - diabetes en hartfalen versterken elkaar. Alhoewel er vele studies zijn 
gedaan naar antidiabetica met speciaal oog voor de effecten op het hart, zijn er relatief 
wcinig data over de cffccten van orale anidiabctica op het proces van remodeling en 
hartfalcn. Dit proefschrift bcschrijft ccn aantal cxpcrimentclc studies waarin is 
bcstudccrd hoe bepaalde oralc antidiabetica het ontstaan van hartfalcn bei"nvloeden. 
In hoofdstuk 1 bespreken we de relatie tussen hartfalen en diabetes. Diabetes en 
hartfalcn zijn bcide grote problemen voor de volksgezondheid; het ziekteverloop van 
hartfalen en diabetes kan elkaar bei"nvloeden en elkaar versterken. Daamaast lijkt hct 
crop dat de aanwezigheid per se van de ene ziekte de anderc ziekte kan uitlokken. 
In hoofdstuk 2 gcvcn we ccn ovcrzicht van de beschikbarc gegcvcns uit cxpcrimentele 
studies, we beschrijvcn de effecten van orale diabetes medicatie op cardialc remodeling 
en hartfalen. We concluderen dat van een aantal behandelingen, met name metformine 
en stoffcn die interfcrercn met hct GLP-1/DPP-4-systcem, is aangetoond dat ze het hart 
bcschermen in verschillende experimentele modellen. Dit wordt wat betreft 
mctforminc ondcrstcund door post-hoc analyses van grate klinische studies. Er zijn 
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geen prospectieve studies uitgevoerd waarbij het effect van behandeling van diabetes 
op hartfalen is onderzocht. Wij stellen voor dat deze studies worden gedaan, bij 
diabetici en wat mogelijk nog interessanter is, in pre-diabetici. 
In hoofdstuk 3 hebben we onderzocht of metformine, het eerstelijns diabetesmiddel, 
beschermende effecten heeft op de cardiale remodeling in een post-MI rat model. Dit 
model wordt gekenmerkt door post-MI hartfalen, waarbij ongeveer 40% van de LV 
wand geinfarceerd is, en geassocieerd is met een significante toename van 
genexpressie kenmerkend voor cardiale remodeling, zoals ANP. Echocardiografische 
en hemodynamische parameters laten zien dat in controle ratten hartfunctie op de lange 
termijn ( 1 0-12 weken) sterk verminderd was na een myocardinfarct. We zagen een 
dunnere linkerkamer wand, dilatatie en een verminderde systolische functie. Daamaast 
zagen we hypertrofie van het hart, blijkend uit vergrote cardiomyocyten, en een 
significante afname van de capillaire dichtheid. 
Behandeling met metformine resulteerde in een kleine afname van de infarct grootte en 
daarbij passende vermindering van cardiale remodeling, zoals blijkt uit verminderde 
ANP expressie (50% reductie), verbetering van de systolische functie en minder 
dilatatie van het linker ventrikel in vergelijking met het onbehandelde myocardinfarct. 
Moleculaire analyses wijzen op een rol voor de veranderende AMPK fosforylatie en 
lage insuline levels als beschermingsmechanismen voor het hart in dit non-diabetische 
post-MI model. Daamaast hebben we onderzocht of een lange duur van hartfalen 
insulineresistentie zou kunnen veroorzaken. Echter, basale bloedsuikerwaarden en de 
orale glucose tolerantie test suggereerde dat er geen insulineresistentie voorkwam 
tijdens de cardiale remodeling en dat metformine hier ook geen effect op had. 
Samengevat, onze resultaten wijzen er op dat metformine potentie heeft om de 
ontwikkeling van hartfalen na MI te remmen, in de afwezigheid van diabetes en 
onafhankelijk van systemische glucoselevels en onafhankelijk van insuline intolerantie. 
In hoofdstuk 4 hebben we het effect van de DPP-4-remmer vildagliptine op post-MI 
cardiale remodeling onderzocht. Vildagliptine maakt deel uit van een nieuwe klasse 
van anti-diabetica, de incretines, waarover gepubliceerd is dat ze ook een beschermend 
effect hebben op het cardiovasculaire systeem. DPP-4 breekt GLP-l snel af, een DPP-
4-remmer verhindert dit en verhoogt daarmee de GLP-1 levels. Onze hypothese was 
dat de DPP-4-remmer vildagliptine een beschermend effect heeft op de hartfunctie in 
een post-MI hartfalen model. 
In deze studie hebben we hetzelfde model gebruikt als in hoofdstuk 3, het post-MI 
hartfalen model. De DPP-4 remmer vildagliptine verhoogde het actieve endogene 
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GLP-l -niveau ongeveer 3 maal, <lit is geassocicerd met een (verwachte) remming van 
70% van de DPP-4-activiteit. Echter, de grootte van het infarct en cardiale functie 
warcn gclijk in de met DPP-4-rcmmer bchandelde dieren en controle dieren. Ook alle 
andcrc metingen van cardiale remodeling waren onveranderd. Mogelijke redenen voor 
<lat DPP-4 rcmming geen effect heeft op de cardiale remodeling in <lit model zijn: de 
doscring, de gebruikte analoog, de bereikte GLP- l levels, de timing van de 
bchandeling en de bestudeerde diersoort. Deze resultaten wijzen crop <lat ondanks de 
stijging van actieve plasma GLP- l levels door remming van de DPP-4-activiteit, een 
langdurige behandeling met de DPP-4-remmer vildagliptine hct hart nict substanticcl 
bcschcrmt in een post-Ml model in ratten. 
In  hoofdstuk 5 wilden we de effecten van de DPP-4 remmer vildagliptine 
onderzockcn in een vroeg stadium van diabetische cardiomyopathie. Omdat de 
incidcntic van diabetes toeneemt verwachten we vaker diabetische cardiomyopathie te 
zien, gckcnmerkt door myocardialc dysfunctie bij diabetes patienten, in de afwczighcid 
van coronairlijden of hypertensie. Op <lit moment zijn er slechts weinig gegevens 
beschikbaar over de effecten van specifieke anti-diabetische behandeling op de 
myocardiale functie en metabolisme. We hebben Zucker Diabetic Fatty (ZDF) rattcn 
gebruikt, <lit zijn ratten met een mutatie in het gen voor de lcptine receptor. Dczc 
mutatic is geassocieerd met obesitas en diabetes. Dit model hcbbcn we gcbruikt om de 
myocardiale veranderingen en mechanismen te bestudcren die relevant zijn voor het 
mctabool syndroom. De dieren ontwikkelen insuline-resistentie in het begin van de 
studic (lecftijd van IO weken), blijkend uit verhoogde glucose- en insulinespiegels. In 
de daarop volgende 15 weken van het experiment daalden de insuline niveaus in de 
ZDF diercn aanzienlijk, wat aangecft <lat de alvleesklier niet mccr functioneerde. 
Het hart van de ZDF ratten toonde ecn gestoorde diastolischc functic, ccn veranderend 
metabolisme en fibrose. Functieparameters E, E/A-ratio, en TVls, gemeten via 
cchocardiografie, waren significant afgenomen in de ZDF-groep in vergelijking met de 
controle Zucker lean ratten. Deze veranderingen waren geassocieerd met mecr 
collageen dcpositie, zowel intcrstiticcl en pcrivasculair, en cen verhoogdc collagecn I 
eiwit expressie. P-38 MAPK en P-PKA wcrden gei"dcntificccrd als potcnticlc 
mechanismcn van de myocardiale dysfunctie en fibrose. Daamaast zijn er 
veranderingen in het myocardiale mctabolismc gevonden in de huidige studie, inclusief 
een afwijkcnde vetstofwisseling en glucose homeostase. Verhoogde NEFA waren 
aanwczig in de ZDF dicren, en de hocvcclhcid myocardiaal glycogeen was significant 
verhoogd. De verhoogdc glycogeen levels rcsultcerden in ecn verminderde fosforylatie 
van GSK-3 en GLUT4. Behandeling met vildagliptine verminderde myocardiale 
fibrose en linker ventrikel stijfbeid in de diabetische dieren, <lit leidde tot een trend van 
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een verbeterde diastolische functie. Deze veranderingen waren geassocieerd met een 
afuame van collageen I levels en fosforylering van p-38 eiwit expressie. Normalisering 
van de glycogeen hoeveelheid en toename van de fosforylatie levels van GSK-3 en 
GLUT4 eiwit wijzen op een verbeterd glucose metabolisme. Dit suggereert <lat 
vildagliptine de opname van glucose verbetert in <lit diabetische diermodel. 
In hoofdstuk 6 hebben we onderzocht of diabetes geassocieerd is met een toegenomen 
incidentie van hartfalen na een coronaire bypassoperatie (CABG) in de IMAGINE 
(lschemia Management with Acupril post bypass Graft via Inhibition of the coNverting 
Enzyme) trial. De IMAGINE was een dubbel-blind, placebo-gecontroleerde, 
gerandomiseerde, internationale multicenter studie om te onderzoeken of een ACE­
remmer, quinapril, vroeg toegediend na CABG de cardiovasculaire mortaliteit en 
morbiditeit zou kunnen verminderen. Van de 2553 patienten had 10% diabetes, 
waarvan 60% werden behandeld met metformine en 24% werden behandeld met 
insuline. Tijdens een follow-up van ongeveer drie jaar (mediaan) was de incidentie van 
de primaire (samengestelde eindpunt van cardiovasculaire dood of reanimatie na een 
hartstilstand, niet-fataal myocardinfarct, coronaire revascularisatie, instabiele angina 
pectoris waarvoor ziekenhuisopname noodzakelijk was, gedocumenteerd angina 
pectoris waarvoor ziekenhuisopname niet noodzakelijk was, beroerte en hartfalen 
waarvoor ziekenhuisopname noodzakelijk was) en secundaire (van de primaire 
eindpunt met de toevoeging van transient ischaemic attack en alle andere 
cardiovasculaire gebeurtenis waarvoor hospitalisatie vereist was) IMAGINE 
eindpunten of "major" coronaire events vergelijkbaar tussen de patienten met en 
zonder diabetes. Echter er was een 3-voudige hogere incidentie van ziekenhuisopname 
ten gevolge van hartfalen bij diabetespatienten. Verder was er een trend naar minder 
ziekenhuisopnames ten gevolge van hartfalen bij patienten met diabetes behandeld met 
metformine, wat duidt op een potentieel beschermend effect voor hartfalen bij diabetes. 
Ook uit deze studie blijkt weer <lat diabetes de kans op hartfalen sterk vergroot, een 
bevinding die consistent is met andere klinische observaties en experimentele studies. 
Metformine lijkt het beste eerste keus middel te zijn. 
Toekomstperspectieven 
Diabetes en hartfalen zijn veelvoorkomende ziekten die invloed op elkaar hebben. Vee! 
ziekten staan niet op zichzelf. Dit geldt voor obesitas, hypertensie, het metabool 
syndroom, en zeker voor diabetes en hartfalen. Deze conditie kan warden omschreven 
als het cardiometabool-syndroom, omdat deze twee ziekten elkaar kunnen versterken 
en elkaar kunnen veroorzaken, <lat wil zeggen <lat patienten met diabetes een hoog 
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risico hebben op hart- en vaatziekten en daaropvolgend hartfalen, en in omgekeerde 
volgorde, hartfalen patienten met diabetes hebben een slechtere uitkomst. Om deze 
reden is het cardiometabool-syndroom het laatste decennium uitgegroeid tot een 
belangrijk nieuw onderwerp in het onderzoek en in de behandeling in de cardiologie. 
Er zijn weinig studies die deze ziektes tegelijkertijd bestuderen, daarom is het aan te 
raden om het spectrum van deze ziekten en niet de twee ziekten afzonderlijk te 
bestuderen. We zullen verdere studies uitvoeren om ans verder te verdiepen in het 
cardiometabool-syndroom, met zowel diabetes en hartfalen. 
Uit zowel klinische studies als experimentele studies blijkt dat antidiabetica niet allcen 
van nut kunnen zijn om glucoselevels te corrigeren, maar dat ze oak rechtstreeks 
invloed kunnen hebben op het hart. Onze experimentele studie toonde aan dat 
metformine cardiale remodeling vermindert in het post-MI niet-diabetische hartfalen 
model 4• Op basis van deze experimentele studie hebben we de hypothese dat 
metformine een potentieel gunstig effect heeft bij niet-diabetische patienten met linker 
ventrikel dysfunctie. Daarom hebben wij een fase IV klinische studie opgezet en 
gestart, met de naam Metformin to Reduce Heart Failure After Myocardial Infarction 
(GIPS-lll, NCT01217307). Deze studie loopt en zal de effecten van metformine bij 
niet-diabetische patienten na een myocardinfarct evalueren. Niet-diabetische patienten 
na een ST-elevatie myocardinfarct warden geselecteerd en krijgen 500mg metformine 
tweemaal daags gedurende 4 maanden. De primaire uitkomst is het effect van 
metformine behandeling op de linker ventrikel ejectiefractie. De incidentie van 
cardiovasculaire gebeurtenissen tijdens de follow-up is de secundaire uitkomst. 
Door de jaren heen zijn er een groat aantal experimentele studies geweest die 
beschermende effecten hebben gerapporteerd van anti-diabetische geneesmiddelen op 
het cardiovasculaire systeem. Het merendeel van deze studies zijn gedaan in niet­
diabetische dieren, zoals beschreven in dit proefschrift. Daarentegen zijn de resultaten 
van het relatief kleine aantal klinische studies tot nu toe meestal negatief of 
tegenstrijdig geweest in hun bevindingen s-s in vergelijking met de gerapporteerde 
experimentel<? data. De verklaring voor deze tegenstrijdige uitkomsten is grotendeels 
onduidelijk, rnaar het benadrukt het belang van grate klinische studies. Zeker voor de 
nieuwere anti-diabetische drugs zoals GLP-1 analogen en DPP-4-remmers zijn er 
veelbelovende en consistente resultaten verkregen uit experimentele studies waarin hun 
potentie om het cardioprotectief te werken duidelijk wordt, rnaar wederom zijn er grate 
klinische trials nodig. De investering in dit onderzoek zal het begrip van het 
werkingsmechanisme van deze geneesmiddelen vergroten en zal zeker nieuwe 
inzichten geven in de relatie tussen diabetes en hartfalen en mogelijke kansen bieden 
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